

NCI

FACT BOOK

**National
Cancer
Institute**

2003

**U.S. DEPARTMENT
OF HEALTH AND
HUMAN SERVICES**

Public Health Service

National Institutes of Health

The information set forth in this publication is compiled and amended annually by the financial management staff of the National Cancer Institute and is intended primarily for use by members of the Institute, principal advisory groups to the Institute and others involved in the administration and management of the National Cancer Program. Questions regarding any of the information contained herein may be directed to the Financial Management Branch, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland, 20892.

TABLE OF CONTENTS

Executive Summary	Fiscal Year 2003 Annual Report..... iii
Organization	Director's Biography O-1 Former Directors of the NCI O-2 National Cancer Advisory Board..... O-3 Boards of Scientific Counselors and Advisors O-7 President's Cancer Panel O-8 Executive Committee Members..... O-8 NCI Director's Consumer Liaison Group..... O-9 Organization Charts: National Cancer Institute O-10 Office of the Director O-11 OD I: Office of Management..... O-12 OD II: Office of the Deputy Director O-13 OD II: Center for Strategic Scientific Initiatives O-13 OD II: Center for Strategic Dissemination O-13 OD III: Office of the Deputy Director for Extramural Science.. O-14 OD IV: Center to Reduce Cancer Health Disparities..... O-15 OD IV: Office of Budget and Financial Management..... O-15 OD IV: Office of Science Planning and Assessment..... O-15 OD IV: Office of Communications..... O-15 Center for Cancer Research.....O-16 Division of Cancer Epidemiology and Genetics O-18 Division of Cancer Prevention O-19 Division of Cancer Control and Population Sciences O-20 Division of Cancer Treatment and Diagnosis..... O-21 Division of Cancer Biology..... O-22 Division of Extramural Activities..... O-23
Cancer Statistics	Number of Deaths for the Five Leading Cancer Sites..... C-1 Relationship of Cancer to the Leading Causes of Death in the U.S. C-1 Estimated New Cancer Cases and Deaths..... C-2 The Cost of Cancer C-3 Average Years of Life Lost Per Person Dying of Cancer C-4 Five-Year Relative Survival Rates by Cancer Site..... C-5 Cancer Incidence Rates C-6 Cancer Mortality Rates Changes from 1992 to 1998 C-7 Cancer Incidence Rates by Race C-8 Cancer Mortality Rates by Race C-9 The Prevalence of Cancer C-10
Budget Data	NCI Budget.....B-1 Program Structure.....B-2 Extramural FundsB-3 NCI Obligations by MechanismB-4 Division Obligations by MechanismB-5 NIH Management Fund, Service & Supply Fund and GSA Rent...B-6 Special Sources of Funds.....B-7 Research Funding for Various Research Areas.....B-8

Extramural Programs	Research Project Grants:	
	Number of Awards.....	E-1
	Requested, Awarded.....	E-2
	Awards by Activity Code.....	E-3
	Activity Code Descriptions.....	E-4
	Cancer Centers	
	By State	E-5
	Specialized Programs of Research Excellence (SPORE).....	E-6
	National Research Service Awards – Pre and Post Doctoral	
	Trainees	E-7
	Construction/Renovation Funding	E-8
Grant and Contract Awards by State	E-9	
Grant and Contract Awards by Country	E-10	
Institutions Receiving More than \$15,000,000 in NCI Support.....	E-11	
Historical Trends	Appropriations of the NCI	H-1
	Bypass Budget Requests	H-2
	Comparison of Bypass Requests and Appropriations of the NCI ..	H-3
	Comparison of Dollars, Positions and Space.....	H-4
	Personnel Resources	H-5
	AIDS Funding History.....	H-6

This publication may be viewed on the World Wide Web by pointing a browser to the Financial Management Branch homepage on the National Cancer Institute's website: www.nci.nih.gov or www.cancer.gov.

Executive Summary

Fiscal Year 2003 Annual Report

BUDGET IN REVIEW

This report provides a summary of the distribution of the Fiscal Year 2003 budget among the various National Cancer Institute (NCI) research programs and funding mechanisms, funding policies influencing grant awards, and comparisons with prior year allocations. Additional information on the NCI budget is accessible from the NCI Home Page (<http://www.cancer.gov>).

Summary

Funds available to the NCI in FY 2003 totaled over \$4.592 billion, reflecting an increase of 10% and \$416 million over the previous fiscal year.

Fiscal highlights from FY 2003 include:

- Of the total NCI budget, 60% of the funds were allocated for Research Grants.
- The total number of Research Project Grants (RPG) funded grew to 5,135.
- Nearly one-fourth of the RPGs awarded were new (Type 1) or competing renewal (Type 2) awards.
- Over 30% of the total NCI budget supported ongoing non-competing (Type 5) RPGs.
- R01 grants were funded to the 20th percentile.
- 356 grants – totaling over \$90 million – were funded as Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards.
- Intramural Research remained at 15% of the total NCI budget in FY 2003.
- Over \$530 million – nearly 12% of the total NCI budget – was allocated for Cancer Prevention & Control.
- 1421 competing RPG's were funded – the most ever in NCI's history.

Distribution of the Budget by Funding Mechanism for FY 2002 and FY 2003

Summary Points

Of the \$416 million increase:

- Over half of the increase – or \$240 million – was allocated for the Research Grants budget mechanisms.
- \$165 million – or 40% of the increase – was provided to the Research Project Grant (RPG) category.
- Within the RPG category, \$92 million of the increase was allocated to cover increased expenses for non-competing grants.
- \$32 million – or 8% of the increase – was provided to the Cancer Prevention & Control budget mechanism.
- Funds for training and career development of current and future research scientists through Research Career Awards grew by 31%; Career Education funding increased by 12%.
- The total budget for Cancer Centers, Specialized Centers (U54) and SPOREs increased by 18%. Since the inception of the new grant activity in FY 2001, the funding of Specialized Centers (U54) has increased by 78%.
- The major factors of the 24% increase in R&D over FY 2002 include \$20 million allocated to NCICB for the Center for Bioinformatics, a Program Evaluation increase of \$24 million and the Loan Repayment Program more than doubled in FY2003 from \$4.2 million to nearly \$9 million.
- During FY 2003, NIH and DHHS Assessments increased a total of \$54 million, including a \$39 million increase for Program Evaluation, a \$4.7 million increase for the Management Fund, and \$10.2 million for other assessments.

NCI Dollars by Mechanism for FY 2002 and FY 2003

(Dollars in Thousands)

	2002	2003	Change 02-03	
			Amount	%
Research Project Grants:				
Noncompeting	\$1,323,942	\$1,416,022	\$92,080	7.0%
Admin Supplements	46,785	60,132	13,347	28.5%
Competing	436,121	491,722	55,601	12.7%
Subtotal, RPG	1,806,848	1,967,876	161,028	8.9%
SBIR/STTR	86,366	90,857	4,491	5.2%
Total, RPG's	1,893,214	2,058,733	165,519	8.7%
Cancer Centers	208,009	235,806	27,797	13.4%
Specialized Cancer Centers (U54)	16,847	19,166	2,319	13.8%
SPOREs	94,897	123,107	28,210	29.7%
Total; Centers, U54s, SPOREs	319,753	378,079	58,326	18.2%
Research Career Program	54,867	71,845	16,978	30.9%
Cancer Education	26,775	30,041	3,266	12.2%
Clinical Cooperative Groups	163,826	158,714	-5,112	-3.1%
Other Grants	58,667	59,766	1,099	1.9%
Subtotal, Other	304,135	320,366	16,231	5.3%
Total, Research Grants	2,517,102	2,757,178	240,076	9.5%
National Research Service Awards	63,674	65,850	2,176	3.4%
R&D Contracts	298,232	370,760	72,528	24.3%
Intramural Research	637,581	693,083	55,502	8.7%
Research Management & Support	153,904	167,302	13,398	8.7%
Cancer Prevention & Control	501,208	533,173	31,965	6.4%
Construction	5,000	5,000	0	0.0%
Total, NCI	4,176,701 *	4,592,346 **	415,645	10.0%
AIDS research included above	[254,396]	[263,442]	[9,046]	3.5%

* Does not include \$1.1 million received by the NCI from the US Postal Service's sale of the Breast Cancer Stamp

** Does not include \$3.1 million received by the NCI from the US Postal Service's sale of the Breast Cancer Stamp


Percent Share of Total NCI Dollars

Summary Points

- The mechanism shares of the total budget have remained relatively stable from FY 1999 to FY 2003
- Intramural Research has remained at 15% of total NCI dollars.

Percent Share of Total NCI Dollars					
	1999	2000	2001	2002	2003
Research Project Grants	47.1%	46.1%	45.2%	45.3%	44.8%
Cancer Centers*	5.3%	5.1%	5.4%	5.4%	5.6%
SPORES	1.5%	1.6%	2.0%	2.3%	2.7%
Clinical Cooperative Groups	4.2%	4.4%	4.1%	3.9%	3.5%
Intramural Research	15.5%	15.3%	15.1%	15.3%	15.1%
R&D Contracts	7.4%	7.6%	7.6%	7.1%	8.1%
Cancer Prevention & Control	10.6%	11.8%	12.2%	12.0%	11.6%
Other Mechanisms	8.5%	8.1%	8.3%	8.7%	8.6%

* FY 2001, 2002 and FY 2003 include funds used for Specialized Cancer Centers (U54)



Funding Trends

Summary Points

- The NCI budget has increased by \$2.06 billion – or 81.7% – since FY 1998.
- All mechanisms, except for Research Project Grants, Intramural Research and Clinical Cooperative Groups have experienced percentage increases greater than the total NCI growth.
- Intramural Research has expanded at the lowest percentage of all mechanisms.

Historical Funding Trends

(Dollars in Millions)

	1998	1999	2000	2001	2002	2003
Total NCI	\$2,527.5	\$2,891.6	\$3,311.1	\$3,753.7	\$4,176.7	\$4,592.3
Research Project Grants	1,230.8	1,361.8	1,528.0	1,696.6	1,893.2	2,058.7
Intramural Research	437.8	448.2	507.8	567.3	637.6	693.1
Cancer Centers*	134.0	153.2	169.1	202.9	224.8	255.0
SPOREs	30.9	42.6	52.3	76.8	94.9	123.1
Clinical Cooperative Groups	93.0	120.2	144.6	154.3	163.8	158.7
Cancer Prevention & Control	249.9	306.3	389.4	459.5	501.2	533.2
R&D Contracts	171.1	214.1	251.6	284.0	298.2	370.8
Other Mechanisms	180.0	245.2	268.3	312.3	363.0	399.7

* FY 2001, 2002 and FY 2003 include funds used for Specialized Cancer Centers (U54)

	1998 to 1999	1999 to 2000	2000 to 2001	2001 to 2002	2002 to 2003	1998 to 2003
Total NCI	14.4%	14.5%	13.4%	11.3%	10.0%	81.7%
Research Project Grants	10.6%	12.2%	11.0%	11.6%	8.7%	67.2%
Intramural Research	2.4%	13.3%	11.7%	12.4%	8.7%	58.3%
Cancer Centers*	14.3%	10.4%	20.0%	10.8%	13.3%	90.2%
SPOREs	37.9%	22.8%	46.9%	23.6%	29.7%	298.4%
Clinical Cooperative Groups	29.2%	20.3%	6.7%	6.2%	-3.1%	70.8%
Cancer Prevention & Control	22.6%	27.1%	18.0%	9.1%	6.4%	113.4%
R&D Contracts	25.2%	17.5%	12.9%	5.0%	24.3%	116.7%
Other Mechanisms	36.2%	9.4%	16.4%	16.2%	10.1%	122.1%

*FY 2001, 2002 and FY 2003 include funds used for Specialized Cancer Centers (U54)

Research Project Grants

Summary Points

- 91% of competing dollars supported grants awarded within the established payline; 9% supported grants as an exception to the payline.
- RFA funds, which increased from the FY 2002 dollar level, accounted for 6% of FY 2003 competing dollars.
- \$2.7 million of funds for Accelerated Executive Review permitted the award of 9 grants.
- Research Project Grant applications submitted to NCI increased by approximately 14%.
- 1421 competing RPG's were funded – the most ever in NCI's history.

Research Project Grants

(Dollars in Thousands)

	2002*		2003**	
	No.	Amount	No.	Amount
Total funding for RPGs	4,976	\$1,893,214	5,135	\$2,058,734
SBIR/STTR	374	\$86,366	356	\$90,857
Funding for RPGs without SBIR/STTR Program	4,602	\$1,806,848	4,779	\$1,967,877
Continuation or noncompeting grants funded	3,338	\$1,278,669	3,358	\$1,357,301
Competing grants funded	1,264	\$436,120	1,421	\$491,722
Administrative Supplements		\$46,785		\$60,132
Partial assessment for DHHS Program Evaluation		\$45,273		\$58,721
Funds set aside within competing dollars for:				
Grants within Paylines:	1,148	\$395,013	1,305	\$445,045
Traditional R01	768	\$247,548	868	\$297,261
Program Projects (P01)	32	\$65,964	35	\$56,276
RFA Grants	34	\$24,987	60	\$24,739
Share of competing grant funds		6.08%		5.03%
Exception Grants	116	\$41,108	116	\$46,677
Share of competing grant funds		9.43%		9.50%
Competing Application Requests	4,588	\$1,655,392	6,298	\$2,126,832
Funding Success Rate	27.5%		27.1%	
Percentile funding for R01 grants	22nd		20th	
Average Cost-Competing		\$345		\$346
Average Reduction from recommended/requested levels		-10%		-10%


*Does not include \$1.1 million received by the NCI from the US Postal Service's sale of the Breast Cancer Stamp

**Does not include \$3.1 million received by the NCI from the US Postal Service's sale of the Breast Cancer Stamp

Grant Funding Paylines

RPG Mechanisms:	2002	2003	
R01 Traditional Grants	22nd	20th	percentile
P01 Program Projects	N/A*	N/A*	priority score
R03 Small Grants	225	225	priority score
R21 Exploratory Phase I	200	185	priority score
R33 Exploratory Phase II	180	155	priority score
R41/R42 STTR	218	195	priority score
R43/R44 SBIR	279	230	priority score

* Formal paylines for P01 grants are determined by the Executive Committee



**National Cancer Institute
Extramural vs. Inhouse Funding**
(\$'s in millions)


Extramural

Mechanism	1998	1999	2000	2001	2002	2003	98-03 % chg.
Research Project Grants	\$1,230.8	\$1,361.8	\$1,528.0	\$1,696.6	\$1,893.2	\$2,058.7	67.3%
Cancer Centers	134.0	153.2	169.1	202.9	224.8	255.0	90.3%
SPOREs	30.9	42.6	52.3	76.8	94.9	123.1	298.4%
Other Research Grants	121.0	199.6	232.7	269.2	304.1	320.3	164.7%
NRSA	47.3	57.2	56.1	57.9	63.7	65.9	39.3%
R&D Contracts	171.1	214.1	251.6	284.0	298.2	370.8	116.7%
Cancer Control Grants	63.8	110.9	165.0	183.7	208.2	221.6	247.3%
Cancer Control Contracts	117.5	103.1	107.8	126.1	135.9	160.0	36.2%
Construction	3.0	3.0	3.5	3.0	5.0	5.0	66.7%
Total Extramural Funds	1,919.4	2,245.5	2,566.1	2,900.2	3,228.0	3,580.4	86.5%

Inhouse

Mechanism	1998	1999	2000	2001	2002	2003	98-03 % chg.
Intramural Research	\$437.8	\$448.2	\$507.8	\$567.3	\$637.6	\$693.1	58.3%
RMS	101.7	105.6	120.6	136.5	154.0	167.3	64.5%
Control Inhouse	68.6	92.3	116.6	149.7	157.1	151.5	120.8%
Total Inhouse Funds	608.1	646.1	745.0	853.5	948.7	1,011.9	66.4%

Total NCI	2,527.5	2,891.6	3,311.1	3,753.7	4,176.7	4,592.3	81.7%
------------------	----------------	----------------	----------------	----------------	----------------	----------------	--------------



Research Career Awards – “K” Program


Summary Points

- The Research Career Award mechanism grew by 31% in FY 2003.
- The number of Research Career Awards increased by 66 in FY2003 from FY2002.
- Both K04 Research Career Development and K11 Physician Investigator Awards have been completely phased out.
- NCI began using K05 Research Scientist Awards and K25 Mentored Quantitative Career Development Awards in FY 2001. The K05 has doubled in size since its inception in FY 2001.
- NCI’s funding in FY 2002 for the K30 Institutional Curriculum Awards, which are administered by the National Heart, Lung, and Blood Institute, was once again \$1.6 million.

Research Career Awards ("K" Program) (Dollars in Thousands)

	2002		2003	
	No.	Amount	No.	Amount
K01 Temin Awards	58	\$8,427	73	\$9,928
K01 Minority Mentored Career Development Award	28	3,312	32	4,281
Subtotal, K01s	86	11,739	105	14,209
K05 Research Scientist Award	10	1,205	12	1,462
K07 Preventive Oncology	75	7,023	88	11,243
K08 Clinical Investigator	134	13,188	141	18,512
K12 Institutional Clinical Oncology Research	11	7,716	15	8,391
K22 Transition Career Development	22	3,359	32	4,876
K23 Patient-Oriented Career	44	4,673	53	6,873
K24 Patient-Oriented Career -- Mid Career	37	4,226	38	4,406
K25 Mentored Quantitative Research Career Development Award	1	138	2	273
	420	53,267	486	70,245
K30 Institutional Curriculum Awards -- Administered by NHLBI	0	1,600	0	1,600
Total Research Career Program	420	54,867	486	71,845

National Cancer Institute
FY 2003
% of Total Research Career Award Funds



Research Dollars by Various Cancers

Summary Points

- Funding for various cancers listed below may overlap
- Funding for cancers listed below do not represent the entire NCI budget

	1998	1999	2000	2001	2002	2003 Estimate	% Change 02-03
Total NCI	\$2,551.3	\$2,891.0	\$3,311.1	\$3,753.7	\$4,176.7	\$4,592.3	10.0%
AIDS	\$225.9	\$239.2	\$244.1	\$237.8	\$254.4	\$265.0	4.2%
Brain & Central Nervous System	54.3	63.5	71.9	80.7	95.2	104.5	9.8%
Breast Cancer	348.7	387.2	438.7	475.2	522.6	564.6	8.0%
Cervical Cancer	58.0	66.3	67.0	72.6	67.6	71.3	5.5%
Colorectal Cancer	121.0	152.9	175.8	207.4	245.0	267.0	9.0%
Head and Neck	41.9	45.9	47.0	50.0	58.9	63.8	8.3%
Hodgkin's Disease	8.3	8.2	9.4	10.2	11.8	12.8	8.5%
Leukemia	103.4	122.2	141.7	154.0	177.2	194.9	10.0%
Liver Cancer	38.1	39.8	46.2	54.5	62.5	67.6	8.2%
Lung Cancer	139.8	151.0	175.0	206.5	237.5	256.6	8.0%
Melanoma	50.3	60.1	67.9	71.8	82.3	90.2	9.6%
Multiple Myeloma	10.8	15.3	18.0	19.7	20.8	21.8	4.8%
Non Hodgkin's Lymphoma	57.1	66.2	70.4	79.5	85.6	92.7	8.3%
Ovarian Cancer	40.8	56.5	65.5	76.9	93.5	101.0	8.0%
Pancreatic Cancer	14.2	17.3	20.0	21.8	33.1	36.5	10.3%
Prostate Cancer	86.9	135.7	203.2	258.0	278.4	311.0	11.7%
Stomach Cancer	8.2	7.6	6.8	9.0	11.4	12.5	9.6%
Uterine Cancer	12.2	13.8	16.0	18.8	23.1	25.2	9.1%

National Cancer Institute

Director's Biography

Andrew C. von Eschenbach, M.D.

Andrew C. von Eschenbach, M.D. is the 12th Director in the 65 year history of the National Cancer Institute. He is a nationally recognized urologic surgeon who formerly directed the Genitourinary Cancer Center and the Prostate Cancer Research Program at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. He also served as special assistant for external affairs to M.D. Anderson's president and held the Roy M. and Phyllis Gough Huffington Clinical Research Distinguished Chair in Urologic Oncology.

A native of Philadelphia, Dr. von Eschenbach received his medical degree from Georgetown University Medical School in 1967. He completed residencies in general surgery and urology at Pennsylvania Hospital in Philadelphia, then was an instructor in urology at the University of Pennsylvania School of Medicine. He served as a Lieutenant Commander in the U.S. Navy Medical Corps.

In 1976, Dr. von Eschenbach went to M.D. Anderson Cancer Center for a fellowship in urologic oncology and was invited to join the faculty the following year. From 1983 to 1996, he was Chairman of the Department of Urology and, since 1985, has also been a Consulting Professor in the Department of Cancer Biology.

In 1996, Dr. von Eschenbach was named the founding director of M.D. Anderson's Prostate Cancer Research Program, comprised of over 60 scientists and clinicians collaborating on integrated translational research in the biology, treatment, epidemiology and prevention of the disease. From 1997 to 1999, he also served as Vice President for Academic Affairs and then as Executive Vice President and Chief Academic Officer, leading a faculty of almost 1,000 cancer researchers and clinicians.

He was a founding member of the National Dialogue on Cancer and, prior to his accepting the position as NCI Director, he was President-elect of the American Cancer Society. Dr. von Eschenbach has contributed more than 200 articles, books and chapters to the scientific literature.

Former Directors of the National Cancer Institute

Richard D. Klausner, M.D.

August 1995 – September 2001

Dr. Klausner was appointed as the Director of the National Cancer Institute (NCI) on August 1, 1995. From 1984 until 1997 he was Chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health & Human Development. Dr. Klausner is well known for his contributions to multiple aspects of cell and molecular biology. Dr. Klausner's research has illuminated the genetics and biochemistry of metals as essential but toxic nutrients for virtually all forms of life, has illuminated the pathways by which molecules traffic and speak to each other within the cell, and has described novel mechanisms by which tumor suppressor genes function.

Samuel Broder, M.D.

December 1988 – March 1995

Dr. Broder joined NCI in 1972 as a Clinical Associate in the Metabolism Branch. In 1981, he became Associate Director for NCI's Clinical Oncology Program. In 1985 he led the laboratory team that discovered the therapeutic effects of AZT and other drugs now approved for the treatment of AIDS including DDI and DDC.

Vincent T. DeVita, Jr., M.D.

January 1980 – June 1980 (Acting)
July 1980 – August 1988

Dr. DeVita joined NCI in 1963 as a Clinical Associate in the Laboratory of Chemical Pharmacology. He served NCI as head of the Solid Tumor Service, Chief of the Medicine Branch, Director of the Division of Cancer Treatment and Clinical Director prior to his appointment as Director of NCI.

Arthur Canfield Upton, M.D.

July 1977 – December 1979

Prior to his tenure as NCI Director, Dr. Upton served as Dean of the School of Basic Health Sciences at the State University of New York at Stony Brook.

Frank Joseph Rauscher, Jr., Ph.D.

May 1972 – October 1976

Dr. Rauscher served as Scientific Director for Etiology, NCI, prior to his appointment as Director of NCI in 1972.

Carl Gwin Baker, M.D.

November 1969 – July 1970 (Acting)
July 1970 – April 1972

During his tenure with PHS, Dr. Baker served as Scientific Director for Etiology, NCI, and as Acting Director of NCI prior to his appointment as Director in July 1970.

Kenneth Milo Endicott, M.D.

July 1960 – November 1969

Dr. Endicott served as Chief of the Cancer Chemotherapy National Service Center, PHS, and as Associate Director, NIH, prior to being appointed Director of NCI in July 1960.

John Roderick Heller, M.D.

May 1948 – June 1960

Dr. Heller joined PHS in 1934 and became Chief of the Venereal Disease Division prior to his appointment as Director of NCI in 1948.

Leonard Andrew Scheele, M.D.

July 1947 – April 1948

Dr. Scheele served in various capacities during his tenure with PHS prior to his appointment as Assistant Chief and, subsequently, Director of NCI in July 1947.

Roscoe Roy Spencer, M.D.

August 1943 – July 1947

Dr. Spencer became NCI's first Assistant Chief and, subsequently, was appointed Director of the Institute in 1943.

Carl Voegtlin, Ph.D.

January 1938 – July 1943

Dr. Voegtlin served as Professor of Pharmacology and Chief of the Division of Pharmacy at the Hygienic Laboratory prior to becoming the first Director of NCI in 1938.

National Cancer Advisory Board

Membership and Term

2004 Chairperson

John E. Niederhuber, M.D., Ph.D.

University of Wisconsin School of Medicine
Madison, WI 53792

2004 Elmer E. Huerta, M.D., M.P.H.

Cancer Risk Assess. & Screening Ctr.
Washington Hospital Center
Washington, DC 20010

2006 Samir Abu-Ghazaleh, M.D.

Avera Cancer Institute
Sioux Falls, SD 57105

2004 Susan M. Love, M.D.

Department of Surgery
University of California School of Medicine
Pacific Palisades, CA 90272

2006 James O. Armitage, M.D.

College of Medicine
University of Nebraska Medical Center
Omaha, NE 68198

2006 Arthur W. Nienhuis, M.D.

St. Jude Children's Research Hospital
Memphis, TN 38101

2008 Moon Shao-Chuang Chen, Jr., Ph.D., M.P.H.

University of California
Davis Cancer Center
Sacramento, CA 95817

2004 Larry Norton, M.D.

Medical Breast Oncology
Evelyn H. Lauder Breast Center
Memorial Sloan-Kettering Cancer Center
New York, NY 10021

2008 Kenneth H. Cowan, M.D., Ph.D.

University of Nebraska Medical Center
Eppley Institute for Cancer Research
Omaha, NE 68198

2008 Marlys Popma

Republican Party of Iowa
Des Moines, IA 50309

2008 Jean B. deKernion, M.D.

Department of Urology
UCLA School of Medicine
Los Angeles, CA 90095

2008 Franklyn G. Prendergast, Ph.D., M.A.

Mayo Clinic Cancer Center
Mayo Foundation
Rochester, MN 55905

2004 Stephen C. Duffy

American Academy of Facial Plastic
& Reconstructive Surg. & International
Federation of Facial Plastic Surg. Societies
Alexandria, VA 22314

2004 Amelie G. Ramirez, Dr.P.H., M.P.H.

Department of Medicine
Chronic Disease Prevention
& Control Research Center
Baylor College of Medicine
San Antonio, TX 78230

2006 Ralph S. Freedman, M.B.B.Ch., Ph.D.

Department of Gynecologic Oncology
University of Texas
Houston, TX 77030

2008 Lydia G. Ryan, M.S.N., P.N.P.

Children's Healthcare of Atlanta
AFLAC Cancer Center
Atlanta, GA 30322

2006 James H. French, M.D.

The Center for Plastic Surgery
Annandale, VA 22003

Executive Secretary

Paulette S. Gray, Ph.D.

Committee Management Officer

Claire Benfer

National Cancer Advisory Board (Continued)

Ex Officio Members

The Honorable Elaine Chao, M.B.A.
Secretary of Labor
Washington, DC 20210

Mark B. McClellan, M.D., Ph.D.
Deputy Commissioner
Food and Drug Administration
Rockville, MD 20857

John Howard, M.D., M.P.H., J.D., LL.M.
Director
National Institute for Occupational
Safety and Health (NIOSH)
Washington, DC 20201

Rachel Levinson
Assistant Director for Life Sciences
Office of Science and Technology Policy
The White House
Washington, DC 20506

Kenneth Olden, Ph. D.
Director
National Institute of Environmental
Health Sciences
National Institutes of Health
Research Triangle Park, NC 27709

Ari Patrinos, Ph. D.
Deputy Director, Office of Biological
and Environmental Research
Office of Energy Research
U.S. Department of Energy
Washington, DC 20585

The Honorable Dr. Robert H. Roswell
Under Secretary for Health
Veterans Health Administration
Department of Veterans Affairs
Washington, DC 20420

Mr. Hal Stratton
Chairman
Consumer Product Safety Commission
Bethesda, MD 20814

The Honorable Tommy G. Thompson
Secretary
Department of Health and Human Services
Washington, DC 20201

Ms. Marianne Lamont Horinko
Acting Administrator
Environmental Protection Agency
Washington, DC 20460

The Honorable Dr. William Winkwerder, Jr.
Assistant Secretary of Defense for Health Affairs
Pentagon
Washington, DC 20301

Elias A. Zerhouni, M.D.
Director
National Institutes of Health
Bethesda, MD 20892

National Cancer Advisory Board (Continued)

Alternates to Ex Officio Members

Steven K. Akiyama, Ph.D.
Associate Director for Research and Training
Division of Intramural Research
National Institute of Environmental Health Sciences
National Institutes of Health
Research Triangle Park, NC 27709
(Kenneth Olden, Ph.D. - NIEHS)

Michael A. Babich, Ph.D.
Directorate for Health Sciences
U.S. Consumer Product Safety Commission
Bethesda, MD 20814
(Mr. Hal Stratton - CPSC)

Raynard Kington, M.D., Ph.D.
Deputy Director
National Institutes of Health
Bethesda, MD 20892
(Elias A. Zerhouni, M.D., - NIH)

Peter Kirchner, Ph.D.
Program Manager
Office of Biological & Environmental Research
Division of Medical Science
U.S. Department of Energy
Germantown, MD 20874-1290
(Ari Patrinos, Ph.D. - DOE)

Hugh W. McKinnon, M.D., M.P.H.
Associate Director for Health
National Risk Management Research
Laboratory (MD-225)
U.S. Environmental Protection Agency
Cincinnati, OH 45268
(Ms. Marianne Lamont Horinko - EPA)

T. G. Patel, M.D., M.A.C.P.
Captain MC USN (Retired)
Program Chief
Veterans Health Administration
Department of Veterans' Affairs
Washington, DC 20420
(The Honorable Dr. Robert H. Roswell - VA)

Richard Pazdur, M.D.
Division Director
Division of Oncology Drugs
Food and Drug Administration
Rockville, MD 20857
(Mark B. McClellan, M.D., Ph.D. - FDA)

John F. Potter, M.D.
Director
United States Military Cancer Institute
Walter Reed Army Medical Center
Washington D.C. 20307
(The Honorable Dr. William Winkwerder, Jr. - DOD)

George Ruby, M.D.
Medical Officer
Office of Occupational Medicine
Department of Labor, OSHA
Washington, DC 20210
(The Honorable Elaine Chao - DOL)

Anita L. Schill, Ph.D., M.P.H., M.A., R.N., COHN-S
Senior Scientist
Office of the Director
National Institute for Occupational Safety
and Health
Washington, DC 20201
(John Howard, M.D., M.P.H., J.D., LL.M. - NIOSH)

Note: Bold print represents Ex Officio Members

National Cancer Advisory Board (Continued)

NCAB Subcommittee Assignments

Subcommittee on Activities and Agenda

Dr. John Niederhuber - Chair
Dr. Ralph S. Freedman
Dr. Susan M. Love
Dr. Arthur W. Nienhuis
Dr. Larry Norton
Ms. Marlys Popma
EXECUTIVE SECRETARY: Dr. Cedric Long
(301) 496-9138

Subcommittee on Cancer Centers

Dr. Arthur W. Nienhuis - Chair
Dr. James O. Armitage
Dr. Kenneth Cowan
Dr. Ralph S. Freedman
Dr. Elmer E. Huerta
Dr. Larry Norton
Dr. Kenneth Olden (NIEHS, Ex Officio)
Dr. Franklyn Prendergast
Dr. Amelie G. Ramirez
EXECUTIVE SECRETARY: Dr. Karen Antman
(301) 496-6511

Subcommittee on Clinical Investigations

Dr. Jean B. deKernion - Chair
Dr. Samir Abu-Ghazaleh
Dr. James O. Armitage
Dr. Kenneth Cowan
Dr. Lester Crawford (FDA, Ex Officio)
Dr. Ralph S. Freedman
Dr. James H. French
Dr. Elmer E. Huerta
Dr. Susan M. Love
Dr. Franklyn Prendergast
EXECUTIVE SECRETARY: Dr. Ellen Feigal
(301) 496-4291

Subcommittee on Planning and Budget

Dr. Larry Norton - Chair
Dr. Moon Shao-Chuang Chen, Jr.
Dr. Jean B. deKernion
Mr. Stephen C. Duffy
Dr. Arthur W. Nienhuis
Dr. Franklyn Prendergast
Dr. Amelie G. Ramirez
EXECUTIVE SECRETARY: Ms. Cherie Nichols
(301) 496-5515

Subcommittee on Special Actions

Dr. Ralph Freedman - Chair
Committee of the Whole
EXECUTIVE SECRETARY: Dr. Paulette Gray
(301) 496-4218

Ad hoc Subcommittee on Communications

Dr. Susan M. Love - Chair
Dr. Samir Abu-Ghazaleh
Dr. Moon Shao-Chuang Chen, Jr.
Mr. Steven C. Duffy
Dr. James H. French
Dr. Elmer E. Huerta
Ms. Marlys Popma
Dr. Amelie G. Ramirez
Ms. Lydia Ryan
EXECUTIVE SECRETARY: Ms. Nelvis Castro
(301) 435-7778

Ad hoc Subcommittee on Bioinformatics Vocabulary

Dr. Moon Shao-Chuang Chen, Jr. - Chair
Dr. Kenneth Cowan
Mr. Steven C. Duffy
Dr. Ralph Freedman
Dr. Elmer E. Huerta
Dr. Susan M. Love
Dr. Franklyn Prendergast
Dr. Amelie G. Ramirez
Ms. Lydia Ryan
EXECUTIVE SECRETARY: Dr. Frank Hartel
(301) 435-3869

Ad hoc Subcommittee on Confidentiality of Patient Data

Dr. Amelie G. Ramirez - Chair
Dr. Samir Abu-Ghazaleh
Dr. Jean B. deKernion
Mr. Stephen C. Duffy
Ms. Lydia Ryan
EXECUTIVE SECRETARY: Dr. Roger Aamodt
(301) 496-7147

Ad hoc Subcommittee on Biomedical Technology

Dr. Eric Lander - Chair
Dr. Moon Shao-Chuang Chen, Jr.
Dr. Peter Kirchner (DOE, Ex Officio)
Dr. John Niederhuber
Ms. Marlys Popma
EXECUTIVE SECRETARY: Ms. Kathleen Schlom
(301) 435-5709

Board of Scientific Counselors Intramural Programs

Subcommittee 1: Clinical Sciences and Epidemiology

Appointees	Expiration of Appointment	Appointees	Expiration of Appointment
Chair - Michael B. Kastan, M.D., Ph.D.	2004		
Carlos L. Arteaga, M.D.	2004	Susan Leigh, RN	2008
Leslie Bernstein, Ph.D.	2006	Daniel M. Medina, Ph.D.	2006
Esteban Celis, M.D., Ph.D.	2008	Richard J. O'Reilly, M.D.	2005
Martin A. Cheever, M.D.	2004	Olufunmilayo F. Olopade, MBBS	2004
Leland Chung, Ph.D.	2008	Alice P. Pentland, M.D.	2005
Chi Van Dang, M.D., Ph.D.	2005	Arthur T. Porter, M.D.	2005
Elizabeth T. Fontham, DrPH	2005	David A. Savitz, Ph.D.	2004
Stanley R. Hamilton, M.D.	2006	David T. Scadden, M.D.	2007
David J. Hunter, MBBS, Sc.D.	2004	Steven G. Self, Ph.D.	2006
Laurence N. Kolonel, M.D., Ph.D.	2005	Margaret Ann Tempero, M.D.	2004
Bruce Korf, M.D., Ph.D.	2008	Michael Thun, M.D.	2005
		Executive Secretary - Abby B. Sandler, Ph.D.	

Subcommittee 2: Basic Sciences

Chair - Thomas Kelly, M.D., Ph.D.	2004		
Frederick W. Alt, Ph.D.	2005	Dan R. Littman, M.D., Ph.D.	2007
Jon C. Clardy, Ph.D.	2004	Guillermina Lozano, Ph.D.	2007
Riccardo Dalla-Favera, M.D.	2008	Brooke T. Mossman, Ph.D.	2005
Sankar Ghosh, Ph.D.	2006	Dinshaw J. Patel, Ph.D.	2005
Stephen S. Hecht, Ph.D.	2004	Martine Roussel, Ph.D.	2008
Nouria T. Hernandez, Ph.D.	2006	Harinder Singh, Ph.D.	2007
David Housman, Ph.D.	2004	Ronald I. Swanstrom, Ph.D.	2006
Katherine Jones, Ph.D.	2008	Thea D. Tlsty, Ph.D.	2006
Richard D. Kolodner, Ph.D.	2005	Gregory L. Verdine, Ph.D.	2004
John Kuriyan, Ph.D.	2005	Cheryl Lyn Walker, Ph.D.	2006
		Eileen White, Ph.D.	2005
		Executive Secretary - Florence E. Farber, Ph.D.	

Board of Scientific Advisors Extramural Programs

Chair - Frederick R. Appelbaum, M.D.	2004		
David B. Abrams, Ph.D.	2006	Kenneth W. Kinzler, Ph.D.	2006
David S. Alberts, M.D.	2006	Herbert Y. Kressel, M.D.	2004
Hoda A. Anton-Culver, Ph.D.	2006	Michael P. Link, M.D.	2007
Esther H. Chang, Ph.D.	2006	Lynn M. Matrisian, Ph.D.	2007
Neil J. Clendeninn, M.D., Ph.D.	2005	W. Gillies McKenna, Ph.D.	2004
Tom M. Curran, Ph.D.	2005	Christine A. Miaskowski, Ph.D.	2005
Mary Beryl Daly, M.D., Ph.D.	2004	Enrico Mihich, M.D.	2004
Raymond N. Dubois, M.D., Ph.D.	2007	John D. Minna, M.D.	2004
H. Shelton Earp III, M.D.	2007	Nancy E. Mueller, Sc.D.	2004
Patricia A. Ganz, M.D.	2007	Mack Roach III, M.D.	2007
Susan B. Horwitz, Ph.D.	2006	Richard L. Schilsky, M.D.	2006
Hedvig Hricak, M.D., Ph.D.	2007	Ellen V. Sigal, Ph.D.	2004
Eric Hunter, Ph.D.	2007	Margaret R. Spitz, M.D., M.P.H.	2007
William G. Kaelin, M.D.	2005	William C. Wood, M.D.	2004
Paula K. Kim	2007	Robert C. Young, M.D.	2004
		Executive Secretary - Paulette S. Gray, Ph.D.	

President's Cancer Panel

LaSalle D. Leffall, Jr. M.D. 2004

Chairman
Charles R. Drew Professor of Surgery
Howard University Hospital
2041 Georgia Avenue, NW
Suite 4000
Washington, DC 20060

Margaret Kripke 2006

Executive Vice President/Chief Academics Officer
University of Texas
M.D. Anderson Cancer Center
Unit 113
1515 Holcombe Boulevard
Houston, TX 77030

Lance E. Armstrong 2005

Founder, Lance Armstrong Foundation
1221 South MoPac Expressway
Suite 320
Austin, TX 78746

Maureen O. Wilson, Ph.D.

Executive Secretary

Executive Committee Members

Andrew C. von Eschenbach, M.D.

Director

Harold P. Freeman, M.D.

Director, Center to Reduce Cancer Health
Disparities

Alan Rabson, M.D.

Deputy Director

Paulette Gray, Ph. D.

Acting Director, Division of Extramural Activities

Anna Barker, Ph.D.

Deputy Director for Strategic Scientific Initiatives

Peter Greenwald, M.D.

Director, Division of Cancer Prevention

Carl J. Barrett, Ph. D.

Director, Center for Cancer Research

John Hartinger

Associate Director for Budget and Finance

Mark Clanton, M.D. M. Ph

Deputy Director, Cancer Care and Delivery Systems

Janis Mullaney

Acting Deputy Director for Management

Robert Croyle, Ph. D.

Director, Division of Cancer Control and
Population Sciences

Dinah Singer, Ph. D.

Director, Division of Cancer Biology

Ellen Feigal, M.D.

Acting Director, Division of Cancer Treatment
and Diagnosis

Joseph Fraumeni, M.D.

Director, Division of Cancer Epidemiology and
Genetics


Sandy Koeneman, M.S., M.P.A.


Executive Secretary

NCI Director's Consumer Liaison Group

Ms. Barbara K. LeStage, Chair American Cancer Society	2004	Mr. Christopher Pablo Asian and Pacific Islander American National Cancer Survivors' Network	2004
Ms. Vernal H. Branch Y-me National Breast Cancer Organization	2004	Ms. Karen Packer Marshalltown Cancer Resource Center	2004
Ms. Susan Lowell Butler Ovarian Cancer National Alliance	2004	Mr. Henry Porterfield Alliance for Prostate Cancer Prevention	2004
Ms. Kathy Giusti Multiple Myeloma Research Foundation	2004	Ms. Nyrvah Richard Self Help for Women with Breast or Ovarian Cancer (SHARE)	2004
Mr. Michael Katz International Myeloma Foundation	2004	Mr. Doug Ulman Lance Armstrong Foundation	2004
Ms. Ruth Lin, AOCN American Cancer Society	2004	Dr. Marisa Weiss Living Beyond Breast Cancer	2004
Ms. Gena Love People Living Through Cancer, Inc.	2004	Ms. Nancy Caliman DCLG Executive Secretary National Cancer Institute Bethesda, MD 20892	


National Cancer Institute






Office of the Director Continued - OD I


Office of Management
 Acting Deputy Director
 Ms. Janis Mullaney
 301-435-2455




Office of the Deputy Director
Deputy Director
Dr. Alan Rabson
301-496-1927





Center for Strategic Scientific Initiatives
Deputy Director for Advanced Technology and Strategic Partnerships
Dr. Anna Barker
301-496-1550



Center for Strategic Dissemination
Director
Dr. Edward Maibach
301-594-1669
Deputy Director
Ms. Jill Bartholomew
301-451-1368








Center for Cancer Research Office of the Director

Director
Dr. J. Carl Barrett
301-496-4345

Principal Deputy Director
Dr. Kathryn Zoon
301-496-4346


Laboratory of Mammary Biology &
Tumorigenesis
Chief
Dr. Barbara Vonderhaar
301-594-9940




**Center for Cancer Research
Office of the Director**

Director
Dr. J. Carl Barrett
301-496-4345

Principal Deputy Director
Dr. Kathryn Zoon
301-496-4346





**Division of Cancer Prevention
Office of the Director**

Director
Dr. Peter Greenwald
301-496-6616

Acting Deputy Director
Dr. Leslie Ford
301-496-0265

Associate Director for Clinical Research
Dr. Leslie Ford
301-496-0265

Office of Preventive Oncology
Chief
Dr. Douglas Weed
301-496-8640

**Chemoprevention Agent
Development Research Group**
Chief
Dr. James Crowell
301-496-8563

**Early Detection
Research Group**
Chief
Dr. John Gohagan
301-496-8544

**Nutritional Science
Research Group**
Chief
Dr. John Milner
301-496-8573

**Community Oncology and
Prevention Trials Research
Group**
Chief
Dr. Lori Minasian
301-496-8541

**Biometry Research
Group**
Chief
Dr. Phillip Prorok
301-496-8556

**Basic Prevention Science
Research Group**
Acting Chief
Dr. Peter Greenwald
301-496-6616


**Cancer Biomarkers
Research Group**
Chief
Dr. Sudhir Srivastava
301-435-1594

**Breast & Gynecologic Cancer
Research Group**
Chief
Dr. Karen Johnson
301-496-8526

**Gastrointestinal & Other
Cancer
Research Group**
Chief
Dr. Ernest Hawk
301-594-2684

**Prostate & Urologic Cancer
Research Group**
Chief
Dr. Howard Parnes
301-594-0920

**Lung & Upper Aerodigestive
Cancer Research Group**
Chief
Dr. Eva Szabo
301-435-1595



Division of Cancer Treatment and Diagnosis Office of the Director

Acting Director
Dr. Ellen Feigal
301-496-6711

Deputy Director
Dr. Ellen Feigal
301-496-6711

Biometrics Research Branch
Chief
Dr. Richard Simon
301-496-4836

Radiation Research Program
Associate Director
Dr. Norman Coleman
301-496-6111

Radiotherapy Development Branch
Chief
Dr. Francis Mahoney
301-496-9360

Molecular Therapeutics Branch
Chief
Dr. Philip Tofilon
301-496-6336

Clinical Radiation Oncology Branch
Chief
Dr. Paul Wallner
301-496-6111

Cancer Therapy Evaluation Program
Associate Director
Dr. Michael Christian
301-496-6138

Investigational Drug Branch
Chief
Dr. Louise Grochow
301-496-1196

Clinical Investigations Branch
Chief
Dr. Richard Kaplan
301-496-2522

Pharmaceutical Management Branch
Chief
Mr. Charles Hall
301-496-5725

Regulatory Affairs Branch
Chief
Dr. Dale Shoemaker
301-496-7912

Clinical Trials Monitoring Branch
Chief
Ms. Joan Mauer
301-496-0510

Clinical Grants and Contracts Branch
Chief
Dr. Roy Wu
301-496-8866

Developmental Therapeutics Program
Associate Director
Dr. Edward Sausville
301-496-8720
Deputy Associate Director
(Vacant)

Information Technology Branch
Chief
Dr. Dan Zaharevitz
301-496-8747

Biological Testing Branch
Chief
Dr. Joseph Mayo
301-846-5065

Biological Resources Branch
Chief
Dr. Stephen Creekmore
301-846-1098

Toxicology and Pharmacology Branch
Chief
Dr. Joseph Tomaszewski
301-496-8777

Screening Technologies Branch
Chief
Dr. Robert Shoemaker
301-846-1064

Natural Products Branch
Chief
Dr. Gordon Cragg
301-846-5387

Drug Synthesis and Chemistry Branch
Chief
Dr. Ven Narayanan
301-496-8795

Grants and Contracts Operations Branch
Chief
Dr. Mary Wolpert-DeFilippes
301-496-8783

Pharmaceutical Resources Branch
Chief
Dr. Rao Vishnuvajjala
301-496-8780

Cancer Diagnosis Program
Associate Director
Dr. Sheila Taube
301-496-8639

Diagnostics Research Branch
Chief
(Vacant)

Resources Development Branch
Chief
Dr. Roger Aamodt
301-496-7147

Technology Development Branch
Chief
Dr. James Jacobson
301-402-4185


Cancer Imaging Program
Associate Director
Dr. Daniel Sullivan
301-496-9531

Diagnostic Imaging Branch
Chief
(Vacant)

Molecular Imaging Branch
Chief
Dr. John Hoffman
301-496-9531

Image-Guided Diagnosis and Therapy Branch
Chief
(Vacant)

Imaging Technology Development Branch
Chief
Dr. Laurence Clarke
301-496-9531



**Division of Extramural
Activities**

Acting Director
Dr. Paulette S. Gray
301-496-5147

Deputy Director
Dr. Paulette S. Gray
301-496-5147

Assistant Director
Dr. Cedric W. Long
301-496-9138

**Office of Extramural
Applications**

Associate Director
Dr. Paulette S. Gray
301-496-5147

**Office of Referral, Review and
Program Coordination**

Associate Director
Ms. Diane Bronzert
301-435-5655

**Applied Information
Systems Branch**

Chief
Mr. James W. Seach
301-496-7047

**Research Analysis and
Evaluation Branch**

Chief
Ms. Marilyn Gaston
301-594-1111

**Research Programs
Review Branch**

Chief
Dr. Olivia T. Bartlett
301-594-2501

**Special Review and
Logistics Branch**

Chief
Dr. Kirt J. Vener
301-496-7174

**Program Coordination and
Referral Branch**

Acting Chief
Dr. Christopher Hatch
301-594-1403

**Resources and Training
Review Branch**

Chief
Dr. David Maslow
301-496-2330

Number of Deaths for the Five Leading Cancer Sites by Age Group and Sex

All Ages		Under 15		15-34		35-54		55-74		75+	
Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
Lung & Bronchus 90,363	Lung & Bronchus 65,606	Leukemia 276	Leukemia 227	Leukemia 589	Breast 470	Lung & Bronchus 8,685	Breast 9,356	Lung & Bronchus 48,540	Lung & Bronchus 32,419	Lung & Bronchus 33,044	Lung & Bronchus 26,957
Prostate 30,719	Breast 41,394	Brain & ONS 205	Brain & ONS 211	Brain & ONS 391	Leukemia 404	Colon & Rectum 3,254	Lung & Bronchus 6,140	Colon & Rectum 12,422	Breast 16,155	Prostate 21,825	Colon & Rectum 16,486
Colon & Rectum 28,229	Colon & Rectum 28,579	Endocrine 91	Endocrine 70	NHL 273	Brain & ONS 249	Brain & ONS 1,811	Colon & Rectum 2,621	Prostate 8,450	Colon & Rectum 9,310	Colon & Rectum 12,373	Breast 15,413
Pancreas 14,466	Pancreas 15,336	Soft Tissue 51	Bone & Joints 39	Soft Tissue 187	Cervix 221	Liver & IBD 1,792	Ovary 2,098	Pancreas 7,089	Ovary 6,278	Pancreas 5,556	Pancreas 8,176
Leukemia 11,894	Ovary 14,414	Bone & Joints 49	Kidney & Renal Pelvis 38	Bone & Joints 184	NHL 173	Pancreas 1,788	Cervix 1,664	Esophagus 5,126	Pancreas 5,937	Leukemia 5,239	NHL 5,932

Source: National Center for Health Statistics (NCHS) Public -use file for 2001 deaths.
NHL = Non Hodgkin's Lymphoma

Relationship of Cancer to the Leading Causes of Death in the United States

Rank	Cause	Number of Deaths	Age Adjusted Rate*	Percent of Total Deaths
	All Causes	2,416,003	850.4	100.0%
1	Heart Disease	700,076	246.4	29.0%
2	CANCER	553,760	195.6	22.9%
3	Cerebrovascular Diseases	163,534	57.5	6.8%
4	Emphysema, Bronchitis & Asthma	123,012	43.5	5.1%
5	Accidents	101,417	35.5	4.2%
6	Diabetes Mellitus	71,371	25.2	3.0%
7	Pneumonia & Influenza	62,029	21.8	2.6%
8	Alzheimers	53,852	18.9	2.2%
9	Nephritis & Nephrosis	39,479	13.9	1.6%
10	Septicemia	32,238	11.4	1.3%
11	Symptoms, Signs and Ill-Defined Conditions	32,211	11.3	1.3%
12	Suicide and Self-Inflicted Injury	30,607	10.7	1.3%
13	Chronic Liver Dis and Cirrhosis of the Liver	27,029	9.5	1.1%
14	Homicide and Legal Intervention	20,672	7.2	0.9%
15	Hypertension without Heart Disease	19,250	6.8	0.8%
	Other and Ill-Defined	385,466	135.4	16.0%

Source: NCHS Public-use file for 2001 deaths.
* Age adjusted rate per 100,000 Population

Estimated New Cancer Cases and Deaths by Sex for All Races 2004

Primary Site	Estimated New Cases			Estimated Deaths		
	Total	Male	Female	Total	Male	Female
All Sites *	1,368,030	699,560	668,470	563,700	290,890	272,810
Oral Cavity and Pharynx	28,260	18,550	9,710	7,230	4,830	2,400
Tongue	7,320	4,860	2,460	1,700	1,100	600
Mouth	10,080	5,410	4,670	1,890	1,070	820
Pharynx	8,250	6,330	1,920	2,070	1,460	610
Other Oral Cavity	2,610	1,950	660	1,570	1,200	370
Digestive System	255,640	135,410	120,230	134,840	73,240	61,600
Esophagus	14,250	10,860	3,390	13,300	10,250	3,050
Stomach	22,710	13,640	9,070	11,780	6,900	4,880
Small Intestine	5,260	2,750	2,510	1,130	610	520
Colon	106,370	50,400	55,970			
Rectum	40,570	23,220	17,350	56730*	28320*	28410*
Anus, Anal Canal, & Anorectum	4,010	1,890	2,120	580	210	370
Liver and Intrahepatic Bile Duct	18,920	12,580	6,340	14,270	9,450	4,820
Gallbladder & Other Biliary	6,950	2,960	3,990	3,540	1,290	2,250
Pancreas	31,860	15,740	16,120	31,270	15,440	15,830
Other Digestive	4,740	1,370	3,370	2,240	770	1,470
Respiratory System	186,550	102,730	83,820	165,130	95,460	69,670
Larynx	10,270	8,060	2,210	3,830	3,010	820
Lung and Bronchus	173,770	93,110	80,660	160,440	91,930	68,510
Other Respiratory	2,510	1,560	950	860	520	340
Bones and Joints	2,440	1,230	1,210	1,300	720	580
Soft Tissues	8,680	4,760	3,920	3,660	2,020	1,640
Skin (excl. basal & squamous)	59,350	31,640	27,710	10,250	6,590	3,660
Melanoma-skin	55,100	29,900	25,200	7,910	5,050	2,860
Other non-epithelial skin	4,910	2,400	2,510	2,340	1,540	800
Breast	217,440	1,450	215,990	40,580	470	40,110
Genital Organs	323,210	240,660	82,550	59,250	30,530	28,720
Cervix Uteri	10,520		10,520	3,900		3,900
Endometrium (uterus)	40,320		40,320	7,090		7,090
Ovary	25,580		25,580	16,090		16,090
Vulva	3,970		3,970	850		850
Vagina and other genital organs, female	2,160		2,160	790		790
Prostate	230,110	230,110		29,900	29,900	
Testis	8,980	8,980		360	360	
Penis and other genital organs, male	1,570	1,570		270	270	
Urinary System	98,400	68,290	30,110	25,880	17,060	8,820
Urinary Bladder	60,240	44,640	15,600	12,710	8,780	3,930
Kidney and Renal Pelvis	35,710	22,080	13,630	12,480	7,870	4,610
Ureter and other urinary organs	2,450	1,570	880	690	410	280
Eye and Orbit	2,090	1,130	960	180	110	70
Brain and Other Nervous System	18,400	10,540	7,860	12,690	7,200	5,490
Endocrine Glands	25,520	6,950	18,570	2,440	1,140	1,300
Thyroid	23,600	5,960	17,640	1,460	620	840
Other Endocrine	1,920	990	930	980	520	460
Lymphomas and Myelomas	62,250	33,180	29,070	20,730	11,090	9,640
Hodgkin Disease	7,880	4,330	3,550	1,320	700	620
Non-Hodgkin Lymphoma	54,370	28,850	25,520	19,410	10,390	9,020
Multiple Myeloma	15,270	8,090	7,180	11,070	5,430	5,640
Leukemia	33,440	19,020	14,420	23,300	12,990	10,310
Lymphocytic Leukemias	12,020	7,160	4,860	6,250	3,550	2,700
Myeloid Leukemias	16,520	8,980	7,540	10,440	5,750	4,690
Other Leukemias	4,900	2,880	2,020	6,610	3,690	2,920
All Other Sites	31,090	15,930	15,160	45,170	22,010	23,160

Source: Cancer Facts & Figures-2004, American Cancer Society (ACS), Atlanta, Georgia 2004.

Excludes basal and squamous cell skin and in situ carcinomas except urinary bladder.

Incidence projections are based on rates from the NCI SEER Program 1979-2000.

* Estimated deaths for colon & rectum cancers are combined.

The Cost of Cancer


Cancer treatment spending has risen but remains stable in proportion to total U.S. treatment spending.

The financial costs of cancer treatment are a burden to people diagnosed with cancer, their families, and society as a whole. Cancer treatment accounted for about \$61 billion in 2002, the most recent year for which there is information. This is just under 5 percent of total U.S. spending for medical treatment. In addition to these direct treatment costs, the additional cost of cancer screening in 2002 is \$5 - \$10 billion. The additional economic burden of cancer due to morbidity and premature mortality in 2002 is estimated to be \$15.5 billion in morbidity costs and \$95.2 billion due to premature mortality, resulting in a total economic burden of cancer in 2002 in excess of \$175 billion.

Year	Amount (\$ in millions)	Percent of All Health Care Expenditures
1963	\$1,279	4.35%
1972	3,872	4.96%
1980	13,049	6.01%
1985	18,104	4.81%
1990	27,458	4.46%
1995	41,200	4.69%
2002	60,900	4.57%


Sources: Brown, ML, Lipscomb J, Snyder C. The burden of illness cancer: economic cost and quality of life. Annual Review of Public Health 2001;22:91-113; NHLBI Fact Book, 2001.

**Average Years of Life Lost
Per Person Dying of Cancer
All Races, Both Sexes, 2001**



Source: NCHS public-use data and 2000 life tables.

5 Year Relative Survival Rates by Site
SEER Program 1995-2000
Males and Females




Data From NCI SEER Program
<http://www.seer.cancer.gov/>

* The relative cumulative rate increased from a prior interval and has been adjusted.


Cancer Incidence Rates

Annual Percent Changes from 1992 to 2001



Cancer Mortality Rates

Annual Percent Changes from 1992 to 2001



Cancer Incidence Rates By Race

SEER, 1992-2001

Cancer Site	Incidence Rates per 100,000				
	Blacks	Whites	Hispanics	Asian/ Pacific Islander	American Indian/ Alaska Native
All Sites	528.1	483.2	355.3	339.9	251.4
Males	718.9	573.4	431.2	395.8	286.3
Females	401.8	425.0	309.3	300.0	228.7
Oral Cavity and Pharynx	13.0	11.1	6.9	8.9	7.7
Esophagus	7.7	4.3	3.2	2.9	3.2
Stomach	13.9	7.8	13.7	17.7	10.6
Colon and Rectum	62.7	53.9	39.3	46.9	36.0
Colon excluding Rectum	48.5	39.1	27.1	31.7	26.0
Rectum and Rectosigmoid Junction	14.2	14.8	12.2	15.1	10.0
Liver and IHBD	6.6	4.4	8.7	13.6	7.1
Pancreas	16.1	10.8	10.0	9.4	7.3
Larynx	6.9	4.0	2.9	1.8	1.2
Lung and Bronchus	82.4	64.0	33.9	43.0	37.1
Males	124.4	82.2	47.9	61.6	51.7
Females	53.7	51.2	24.4	28.3	25.9
Melanoma of the Skin	1.0	18.9	4.0	1.5	2.0
Breast(females)	120.3	138.3	88.3	92.2	60.4
<50 years	43.8	43.1	31.8	37.2	21.7
50+ years	320.5	387.6	236.5	236.1	161.7
Cervix Uteri	12.8	9.4	17.7	10.9	6.9
Corpus and Uterus, NOS	18.0	26.1	16.5	16.8	9.9
Ovary	10.3	15.1	11.7	10.2	9.2
Prostate	284.6	175.6	143.0	105.0	62.9
Testis	1.3	6.0	3.4	2.0	2.4
Urinary Bladder	12.5	22.3	10.8	9.6	5.0
Kidney and Renal Pelvis	12.8	11.3	10.6	6.2	11.1
Brain and Other nervous system	4.0	7.1	5.0	3.5	2.3
Thyroid	3.8	6.8	6.2	7.8	3.9
Hodgkin lymphoma	2.4	2.9	2.3	1.0	^
Non-Hodgkin lymphoma	14.4	20.1	16.1	13.6	8.0
All Sites Except Lung and Bronchus	445.8	419.1	321.4	296.9	214.3
Males	594.4	491.2	383.4	334.1	234.6
Females	348.1	373.7	284.9	271.6	202.8

Data source: NCI SEER Program.

NCI's SEER Program, adjusted to the 2000 US population age distribution. Rates for Hispanics exclude cases diagnosed in Detroit and Hawaii.

^ Statistic not shown. Rate based on less than 25 cases for the time interval.

Cancer Mortality Rates By Race United States, 1992-2001

Cancer Site	Mortality Rates per 100,000				
	Blacks	Whites	Hispanics	Asian/ Pacific Islander	American Indian/ Alaska Native
All Sites	261.5	201.8	138.1	126.6	136.2
Males	364.7	254.3	177.1	157.9	168.1
Females	200.1	168.6	112.4	103.0	115.1
Oral Cavity and Pharynx	4.8	2.8	1.9	2.6	2.3
Esophagus	7.5	4.0	2.5	2.2	2.7
Stomach	9.7	4.4	7.4	10.0	5.5
Colon and Rectum	28.8	21.3	14.2	13.6	13.7
Liver and IHBD	6.0	4.0	7.1	10.8	5.6
Pancreas	14.5	10.3	8.4	7.5	6.2
Larynx	2.9	1.3	1.1	0.5	1.1
Lung and Bronchus	67.4	57.1	25.7	29.0	36.6
Males	110.7	80.0	40.9	41.6	51.0
Females	39.2	41.0	14.8	19.2	26.2
Melanoma of the Skin	0.5	3.0	0.8	0.4	0.6
Breast(females)	36.4	28.3	17.9	12.9	14.5
<50 years	11.0	6.2	4.8	4.0	3.2
50+ years	103.0	86.3	52.3	36.1	43.9
Cervix Uteri	6.3	2.7	3.9	3.0	3.2
Corpus and Uterus, NOS	7.0	3.9	3.2	2.2	2.5
Ovary	7.6	9.3	6.3	4.7	5.1
Prostate	74.9	31.8	25.0	14.7	22.3
Testis	0.1	0.3	0.3	0.1	^
Urinary Bladder	4.0	4.5	2.4	1.8	1.6
Kidney and Renal Pelvis	4.2	4.3	3.8	1.9	4.8
Brain and Other nervous system	2.7	5.0	2.9	1.9	2.0
Thyroid	0.4	0.5	0.6	0.7	0.3
Hodgkin lymphoma	0.5	0.5	0.6	0.2	0.2
Non-Hodgkin lymphoma	5.8	8.8	6.5	5.3	4.6
All Sites Except Lung and Bronchus	194.1	144.7	112.4	97.6	99.6
Males	254.0	174.2	136.2	116.3	117.1
Females	160.9	127.6	97.6	83.8	89.0

Data source: NCHS public-use data files. Rates for Hispanics exclude cases diagnosed in Connecticut, Maine, Maryland, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.

^ Statistic not shown. Rate based on less than 25 cases for the time interval.

**The Prevalence of Cancer:
Estimated Number of Persons
Diagnosed With Cancer
United States, 2000**

Primary Site	Estimated Prevalence		
	Total [^]	Males	Females
ALL SITES^a	9,555,312	4,241,699	5,313,613
Brain and Central Nervous System	97,682	52,703*	44,979*
Breast(female)	2,197,504		2,197,504
Cervix	231,064		231,064
Colon and Rectum	1,041,499	499,018	542,481
Corpus and Uterus	556,640		556,640
Esophagus	21,528	16,038	5,490
Hodgkin Lymphoma	131,279	66,925*	64,354*
Kidney and Renal Pelvis	202,073	119,642	82,431
Larynx	98,831	79,181*	19,650*
Leukemia	178,406	99,956	78,450
Acute Lymphocytic Leukemia	39,955#	22,015#	17,940#
Lung and Bronchus	342,457	174,547	167,910
Melanoma of the Skin	550,860	267,432*	283,428*
Non-Hodgkin Lymphoma	314,400	162,106	152,294
Oral Cavity and Pharynx	221,408	142,935	78,473
Ovary	202,949		202,949*
Pancreas	23,534	11,364	12,170
Prostate	1,637,208	1,637,208	
Stomach	59,527	33,905	25,622
Testis	150,851	150,851*	
Thyroid	292,555	65,022*	227,533*
Urinary Bladder	479,136	353,533	125,603
Childhood (0-19 yrs)	194,091#	99,133#	94,958#

Source: U.S. 2000 cancer prevalence rates are based on 2000 cancer prevalence proportions from the nine SEER registries and 1/1/2000 population estimates based on the average of 1999 and 2000 population estimates from the U.S. Bureau of the Census.

^a The All Sites figures are estimates based on all cancer sites, not just those listed here.

[^] The total column represents prevalence estimates using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). Totals are obtained by summing males and females and not by modeling.

* Completeness index was approximated using empirical data from historical Connecticut tumor registry by age at prevalence

Current methodology does not allow for the estimation of complete prevalence for childhood cancer or acute lymphocytic leukemia. Estimates shown are 25 year limited-duration prevalence.

Fiscal Year 2003 Budget

(Dollars in Thousands)

A. Actual Obligations Resulting From Appropriated Funds:

FY 2003 Appropriation	\$4,622,394
Real transfer to other HHS Agencies through .65% Reduction	-30,046
Lapse	-2
Actual Obligations Subtotal	4,592,346

B. Reimbursable Obligations:


Reimbursements	16,653
-----------------------	---------------

C. Total NCI Obligations: \$4,608,999 *

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds. In FY 2003, there were 11 R21 awards for \$3,130.

Program Structure Fiscal Year 2003

(Dollars in Thousands)




Budget Activity	Amount	Percent
Research:		
Cancer Causation	\$1,119,996	24.4%
Detection and Diagnosis Research	318,433	6.9%
Treatment Research	1,055,451	23.0%
Cancer Biology	723,685	15.8%
Subtotal Research	3,217,565	70.1%
Resource Development:		
Cancer Centers Support	379,069	8.3%
Research Manpower Development	168,642	3.7%
Construction	5,199	0.1%
Subtotal Resource Development	552,910	12.0%
Cancer Prevention and Control	517,911	11.3%
Program Management and Support	303,960	6.6%
*Total NCI	4,592,346	100.0%

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds. In FY 2003, there were 11 R21 awards for \$3,130.

Extramural Funds Fiscal Year 2003

(Dollars in Thousands)



Mechanism	Amount	Percent
Contracts:		
R&D Contracts	\$334,313	9.3%
Interagency Agreements	51,258	1.4%
Cancer Control Contracts	145,189	4.1%
Construction Contracts	2,000	0.1%
Subtotal Contracts	532,760	14.9%
Grants:		
Research Project Grants	2,058,733	57.5%
Cancer Centers/SPORES	378,079	10.6%
Training Activities	65,850	1.8%
Other Research Grants	320,368	9.0%
Cancer Control Grants	221,620	6.2%
Construction Grants	3,000	0.1%
Subtotal Grants	3,047,650	85.1%
Total Extramural Funds	3,580,410	100.0%
Total Intramural/RMS/Control Inhouse	1,011,936	
*Total NCI	\$4,592,346	

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds. In FY 2003, there were 11 R21 awards for \$3,130.

NCI Obligations by Mechanism, Fiscal Year 2003

(Dollars in Thousands)

		Number	Amount	% of Total
Research Project Grants	Non-Competing	3,358	\$1,416,022	30.8%
	Administrative Supplements	(285)	60,132	1.3%
	Competing	1,421	491,722	10.7%
	Subtotal, without SBIR/STTR Grants	4,779	1,967,876	43.2%
	SBIR/STTR Grants-R41-44	356	90,857	2.0%
	Subtotal, Research Project Grants	5,135	2,058,733	45.2%
Centers & SPORES	Cancer Centers Grants-P30	61	235,806	5.1%
	SPORES-P20/P50	47	123,107	2.7%
	U54s	14	19,166	0.4%
	Subtotal, Centers	122	378,079	8.2%
Other Research	Career Program			
	Temin & Minority Mentored Awards-K01	105	14,210	0.3%
	RCDA-K04	0	0	0.0%
	Estab. Inv. Award-K05	12	1,462	0.0%
	Preventive Oncology-K07	88	11,243	0.2%
	Clinical Investigator-K08	141	18,512	0.4%
	Physician Investigator-K11	0	0	0.0%
	Clinical Oncology-K12	15	8,391	0.2%
	Transitional Career Development-K22	32	4,876	0.1%
	Mentored Patient Oriented RCDA-K23	53	6,873	0.2%
	Mid-Career Invest. & Patient Orient. Res-K24	38	4,406	0.1%
	Mentored Quant. Res Career-K25	2	273	0.0%
	Inst. Curr. Award-K30	0	1,599	0.0%
	Subtotal, Career Program	486	71,845	1.6%
	Cancer Education Program-R25	102	30,041	0.7%
	Clinical Cooperative Groups-U10	78	158,714	3.5%
	Biomedical Research Support-S07/S10	0	3,842	0.1%
	Minority Biomedical Support-S06	0	3,853	0.1%
	Scientific Evaluation-U09/T09	1	8,085	0.2%
	Continuing Education	4	340	0.0%
	Resource Grants-R24/U24	54	29,976	0.7%
	Explor Coop Agreement-U56	26	11,560	0.3%
	Conference Grants-R13	104	2,112	0.1%
Subtotal, Other Research Grants	855	320,368	7.0%	
Subtotal, Research Grants		6,112	2,757,180	60.0%
NRSA Fellowships	<i>Trainees:</i>	1,520	65,850	1.4%
R&D Contracts	R&D Contracts	267	364,965	8.0%
	SBIR Contracts	24	2,582	0.1%
	NIH Management Fund		3,211	0.1%
	Subtotal, Contracts	291	370,758	7.2%
Intramural Research	Program	1,983	568,255	12.4%
	NIH Management Fund		124,828	2.7%
	Subtotal, Intramural Research	<i>FTEs:</i>	1,983	693,083
RMS	Research Mgmt and Support	713	152,196	3.3%
	NIH Management Fund		15,106	0.3%
	Subtotal, RMS	<i>FTEs:</i>	713	167,302
Cancer Prevention and Control	Cancer Control Grants	191	221,620	4.8%
	Cancer Control Contracts	174	160,002	3.5%
	Inhouse	470	147,601	3.6%
	NIH Management Fund		3,950	0.1%
	Subtotal, Prevention and Control	<i>FTEs:</i>	470	533,173
Construction			5,000	0.1%
*Total NCI	<i>FTEs:</i>	3,166	4,592,346	99.2%

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds. In FY 2003, there were 11 R21 awards for \$3,130.


Division Obligations by Mechanisms, Fiscal Year 2003

(Dollars in Thousands)

CCR	DCEG	DCTD	DCB	DCCPS	DCP	DEA	OD	Research Grants	Program Support
								\$1,357,301	\$58,721
								60,132	
								491,722	
								1,909,155	58,721
								90,857	
								2,000,012	58,721
		3,064					\$232,742		
							123,107		
		5,970	\$1,000				12,196		
		9,034	1,000				368,045		
							14,210		
							1,462		
							11,243		
							18,512		
							8,391		
							4,876		
							6,873		
							4,406		
							273		
							1,599		
							71,845		
							30,041		
								158,714	
								3,842	
								3,853	
								8,085	
								340	
								29,976	
								11,560	
								2,112	
							101,886	218,482	
		9,034	1,000				469,931	2,218,494	58,721
							65,850		
	\$12,702	98,071	4,118	\$29,250			178,971		41,853
	300	519	789	874			100		
									3,211
	13,002	98,590	4,907	30,124			179,071		45,064
\$378,916	48,849	766					112,121		27,603
									124,828
378,916	48,849	766					112,121		152,431
		34,075	10,950			\$15,927	70,876		20,368
									15,106
		34,075	10,950			15,927	70,876		35,474
		19,456		60,654	123,300		18,210		
	5,866	5,513		32,888	92,192		23,543		
4,932	12,366	6,927		28,797	19,183		73,776		1,620
									3,950
4,932	18,232	31,896		122,339	234,675	0	115,529		5,570
							5,000		
383,848	80,083	174,361	16,857	152,463	234,675	15,927	1,018,378	2,218,494	297,260

NIH Management Fund, Service & Supply Fund, and GSA Rent Fiscal Year 2003

(Dollars in Thousands)



DISTRIBUTION OF NCI PAYMENT	Amount	Share of NCI
Clinical Center	\$92,957	63.2%
Center for Scientific Review	7,987	5.4%
Center for Information Technology	5,578	3.8%
Service & Supply Fund	12,704	8.6%
Other Research Services	10,733	7.3%
Other OD	17,136	11.7%
*Total Management Fund and SSF	147,095	100.0%
Other NIH Institutes Management Fund	397,525	
Total NIH Management Fund	\$544,620	

*Excludes GSA Rental Payments for Space which totaled \$37,197 in FY 2003

The Management Fund provides for the financing of certain common research and administrative support activities which are required in the operations of NIH:

Clinical Center: Admissions and followup, anesthesiology, diagnostic x-ray, nuclear medicine, clinical pathology, blood bank, rehabilitation medicine, pharmacy, medical records, nursing services, patient nutrition service, housekeeping services, laundry, and social work

Center for Scientific Review: Initial scientific review of applications, assignment of research grant applications to institutes

Center for Information Technology: Research and development program in which concepts and methods of computer science are applied to biomedical problems

GSA Rental Payments for Space: All building rental, including utilities and guard services.

Other Research Services: Procurement, safety, engineering, biomedical engineering, veterinary resources, and library

Service & Supply Fund: Animal support, collaborative research, conference services, hazardous waste management, interpreting services, library, occupational health and safety, property management support, radiation safety

Special Sources of Funds

CRADAs

As a result of the Federal Technology Transfer Act of 1986 (PL 99-502), government laboratories are authorized to enter into Cooperative Research and Development Agreements (CRADAs) with private sector entities. Licensing agreements are usually incorporated into the CRADA document which addresses patent rights attributable to research supported under the CRADA.

CRADA Receipts Deposited to the U.S. Treasury (Dollars in Thousands)

Fiscal Year	Carryover from Prior Year	Collections	Obligations
1994	1,503	2,272	1,327
1995	2,448	2,811	1,395
1996	3,864	2,017	1,394
1997	4,486	13,378	6,639
1998	11,217	5,351	7,266
1999	9,302	3,645	4,707
2000	8,240	2,717	4,618
2001	6,339	5,295	2,770
2002	8,864	5,048	2,380
2003	11,533	5,171	5,362

Royalty Income

NCI retains a portion of the royalty income generated by the patents related to NCI-funded research. A major portion of this royalty income is used to reward employees of the laboratory, further scientific exchange and for education and training in accordance with the terms of the Federal Technology Transfer Act (PL 99-502). Receipts are also used to support costs associated with processing and collecting royalty income and for technology transfer efforts in NCI and NIH.

Royalty Income Funding History (Dollars in Thousands)

Years	Collections*	Inventor Payments	Other
1994/1995	11,244	1,235	10,009
1995/1996	9,031	953	8,078
1996/1997	13,598	2,175	11,423
1997/1998	9,814	2,321	7,493
1998/1999	22,716	5,084	17,632
1999/2000	21,160	4,695	16,465
2000/2001	37,040	4,811	32,229
2001/2003	27,443	6,210	21,233
2002/2004	42,565	3,961	38,604
2003/2005	27,270	5,799	21,471

* Does not include assessments by NIH.

Stamp Out Breast Cancer

The Stamp Out Breast Cancer Act (PL 105-41) was established in August 1997 and extended in July 2000 (PL 106-253). This act allows postal customers to contribute to funding for breast cancer research through their voluntary purchases of special rate postage stamps from the U.S. Postal Service. The Act required the USPS to transfer 70% to NIH and 30% to the DOD of the funds collected above the postage costs and administrative costs. As of November 2003, NCI has received \$24,087,258. NCI has used these funds for research projects directed towards breast cancer research. Thus far, two major programs have been funded -- the "Insight Awards to Stamp Out Breast Cancer" and the "Breast Cancer Research Stamp Exception Program." In FY 2003, 11 R21 grants were awarded.

Research Funding for Various Research Areas


(Dollars in Millions)

The National Cancer Institute reports how appropriated funds are spent in a number of different categories or classifications including specific cancer sites, cancer types, diseases related to cancer, as well as types of research mechanisms. The table below represents funding levels for frequently requested research areas. These research areas do not represent the entire NCI research portfolio. Funding for these areas can overlap and do not add to the total NCI budget. For example, dollars for a clinical trial on breast cancer research would be included in both the Breast Cancer and the Clinical Trials lines in the table below. Similarly, a basic cancer research project may be relevant to cervical, uterine and ovarian cancers and relevant funding would be included in the figures for all three sites.

Disease Area	1999 Actual	2000 Actual	2001 Actual	2002 Actual	2003 Actual
Total NCI Budget	\$2,891.0	\$3,311.1	\$3,753.7	\$4,176.7	\$4,592.3
AIDS	239.2	244.1	237.8	254.4	263.4
Brain & CNS	63.5	71.9	80.7	95.2	111.5
Breast Cancer	387.2	438.7	475.2	522.6	548.7
Cervical Cancer	66.3	67.0	72.6	67.6	79.0
Colorectal Cancer	152.9	175.8	207.4	245.0	261.6
Head and Neck Cancers	45.9	47.0	50.0	58.9	77.7
Hodgkins Disease	8.2	9.4	10.2	11.8	16.5
Leukemia	122.2	141.7	154.0	177.2	200.9
Liver Cancer	39.8	46.2	54.5	62.5	63.7
Lung Cancer	151.0	175.0	206.5	237.5	273.5
Melanoma	60.1	67.9	71.8	82.3	90.7
Multiple Myeloma	15.3	18.0	19.7	20.8	26.3
Non Hodgkin's Lymphoma	66.2	70.4	79.5	85.6	95.2
Ovarian Cancer	56.5	65.5	76.9	93.5	99.4
Pancreatic Cancer	17.3	20.0	21.8	33.1	42.3
Prostate Cancer	135.7	203.2	258.0	278.4	305.2
Stomach Cancer	7.6	8.2	9.0	11.4	13.4
Uterine Cancer	13.8	16.0	18.8	23.1	25.5

Research Project Grants Number of Awards Fiscal Years 1994 - 2003

Includes Small Business Innovation Research and Small Business Technology Transfer Awards



RPGs Requested and Awarded Fiscal Years 1994 - 2003

(Dollars in Thousands)

Fiscal Year	Type	Requested		Awarded		Success Rate	
		No.	Amt.	No.	Amt.		
1994	Competing	New	3,643	\$787,824	657	\$118,403	21.1%
		Renewal	935	342,068	308	110,723	
		Supplement	20	3,311	4	733	
		Subtotal	4,598	1,133,203	969	229,859	
	Non-Competing			2,436	704,665		
	Total			3,405	934,524		
1995	Competing	New	3,345	\$789,560	645	\$119,760	23.3%
		Renewal	1,048	403,577	375	127,065	
		Supplement	21	7,502	10	1,537	
		Subtotal	4,414	1,200,639	1,030	248,362	
	Non-Competing			2,333	704,374		
	Total			3,363	952,736		
1996	Competing	New	3,071	\$733,313	682	\$142,249	27.5%
		Renewal	947	367,270	422	139,995	
		Supplement	10	1,921	5	694	
		Subtotal	4,028	1,102,504	1,109	282,938	
	Non-Competing			2,381	751,592		
	Total			3,490	1,034,530		
1997	Competing	New	3,328	\$828,653	815	\$160,763	29.2%
		Renewal	815	354,054	392	146,912	
		Supplement	14	3,136	5	755	
		Subtotal	4,157	1,185,843	1,212	308,430	
	Non-Competing			2,532	814,885		
	Total			3,744	1,123,315		
1998	Competing	New	3,054	\$797,477	847	\$189,746	32.8%
		Renewal	697	283,562	382	137,764	
		Supplement	18	4,299	6	1,421	
		Subtotal	3,769	1,085,338	1,235	328,931	
	Non-Competing			2,723	901,845		
	Total			3,958	1,230,776		
1999	Competing	New	3,905	\$1,091,110	1,088	\$237,187	31.8%
		Renewal	757	340,075	390	145,623	
		Supplement	12	3,882	6	2,353	
		Subtotal	4,674	1,435,067	1,484	385,163	
	Non-Competing			2,867	976,610		
	Total			4,351	1,361,773		
2000	Competing	New	4,116	\$1,253,002	957	\$251,628	27.2%
		Renewal	839	435,207	392	175,908	
		Supplement	11	2,379	2	231	
		Subtotal	4,966	1,690,588	1,351	427,767	
	Non-Competing			3,175	1,100,234		
	Total			4,526	1,528,001		
2001	Competing	New	4,342	\$1,374,538	1,050	\$290,707	27.3%
		Renewal	856	437,455	372	173,722	
		Supplement	29	11,108	6	1,214	
		Subtotal	5,227	1,823,101	1,428	465,643	
	Non-Competing			3,267	1,213,098		
	Total			4,695	1,678,741		
2002	Competing	New	4,539	\$1,407,475	1,142	\$302,217	28.4%
		Renewal	861	404,789	384	186,087	
		Supplement	42	8,512	21	3,499	
		Subtotal	5,442	1,820,776	1,547	491,803	
	Non-Competing			3,429	1,356,138		
	Total			4,976	1,847,941		
2003	Competing	New	5,323	\$1,675,039	1,222	\$347,446	26.5%
		Renewal	955	447,122	441	194,084	
		Supplement	20	4,671	5	1,338	
		Subtotal	6,298	2,126,832	1,668	542,868	
	Non-Competing			3,467	1,457,144		
	Total			5,135	2,000,012		

Includes Small Business Innovation Research and Small Business Technology Transfer Awards.

Success rate is the number of awarded grants divided by the number of awards requested.

The requested data excludes applications not recommended for further review.


In FY 2003, the total excludes Program Evaluation Dollars at \$58,721 and R21 Stamp Dollars at \$3,130.

RPG Awards by Activity Code

Fiscal Years 1994 - 2003*

(Dollars in Thousands; Activity Code Descriptions on next page)

		R01	P01	R35	R37	R29	RFA	U01	R03	R21	R33	R15	R55	SBIR/ STTR	TOTAL
1994	#	1,914	163	72	154	312	319	232	46	5			9	179	3,405
	\$	434,612	184,852	61,369	48,699	32,610	70,879	75,444	2,393	353			540	22,773	934,524
1995	#	1,808	149	67	142	342	314	253	44	34			19	191	3,363
	\$	439,122	171,524	63,032	45,125	36,014	72,409	81,771	2,488	7,640			1,126	32,485	952,736
1996	#	1,964	144	65	110	388	268	226	85	46			14	180	3,490
	\$	504,398	182,609	62,550	37,070	41,170	66,102	88,962	5,443	9,599			984	35,643	1,034,530
1997	#	2,194	149	63	90	446	195	169	101	63			21	253	3,744
	\$	583,116	202,317	62,892	30,950	47,413	48,148	81,193	6,411	12,269			1,450	47,156	1,123,315
1998	#	2,454	160	57	75	485	132	157	97	76		2	14	249	3,958
	\$	672,873	228,854	57,712	27,212	52,136	42,750	79,370	6,069	11,782		127	684	51,207	1,230,776
1999	#	2,796	169	38	71	413	261	31	108	159	6	2	6	291	4,351
	\$	775,961	249,583	38,585	27,377	45,361	112,868	21,319	7,355	22,548	2,079	200	620	57,917	1,361,773
2000	#	3,011	179	21	60	314	269	18	100	223	20	0	5	306	4,526
	\$	898,764	286,234	19,413	24,688	34,769	132,872	13,617	7,034	32,897	10,074	99	450	67,090	1,528,001
2001	#	3,231	178	1	61	210	260	18	122	231	49	3	3	328	4,695
	\$	1,008,199	301,115	2,186	26,682	23,738	150,224	14,873	9,024	42,326	23,883	358	300	75,833	1,678,741
2002	#	3,376	173	0	65	112	267	17	186	308	79	10	9	374	4,976
	\$	1,093,908	317,632	0	29,445	12,471	177,195	17,531	14,115	57,633	39,317	1,477	850	86,367	1,847,941
2003	#	3,573	178	0	70	14	252	27	203	360	81	21	0	356	5,135
	\$	1,207,387	336,607	0	35,360	1,584	173,342	31,126	15,207	67,742	37,714	3,086	0	90,857	2,000,012



*EXCLUDES projects awarded with Stamp Out Breast Cancer funds. In FY 2003, there were 11 R21 awards for \$3,130.

Activity Code Descriptions

R01	Research Project (Traditional) discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his/her specified interest and competencies.
P01	Research Program Projects broadly based, multidisciplinary, often long-term, research program which has a specific major objective or a basic theme. A program project is directed toward a range of problems having a central research focus in contrast to the usually narrower thrust of the traditional research project.
R35	Outstanding Investigator Grants long-term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential in a categorical program area.
R37	Method to Extend Research in Time (MERIT) Award long-term grant support to investigators whose research competence and productivity are distinctly superior and who are highly likely to continue to perform in an outstanding manner. Investigators may not apply for a MERIT award. Program staff and/or members of the cognizant National Advisory Council/Board will identify candidates for the MERIT award during the course of review of competing research grant applications prepared and submitted in accordance with regular PHS requirements.
R29	First Independent Research Support and Transition (FIRST) Award sufficient initial period of research support for newly independent biomedical investigators to develop their research capabilities and demonstrate the merit of their research ideas.
RFA	Request for Applications A formal statement inviting grant or cooperative agreement applications in a well-defined scientific area to accomplish specific program purposes and indicates the amount of funds set aside for the competition and/or the estimated number of awards to be made.
U01	Research Project (Cooperative Agreement) discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his/her specific interest and competencies.
R03	Small Grants research support specifically limited in time and amount for studies in categorical program areas. Small grants provide flexibility for initiating studies, which are generally for preliminary short-term projects and are non-renewable.
R21	Exploratory/Developmental Grants Phase I development of new research activities in categorical program areas. Support generally is restricted in level of support and in time.
R33	Exploratory/Developmental Grants Phase II development of new research activities in categorical program areas. Support generally is restricted in level of support and in time.
R15	Academic Research Enhancement Award (AREA) to domestic health professional schools and other institutions offering baccalaureate or advanced degrees in health sciences, except those that have received NIH research grants and/or cooperative agreements. Supports feasibility studies and other small-scale research projects.
R55	Shannon Awards limited support to scientists whose research applications fall short of the cutoff for funding yet are at the "margin of excellence" whereby the perceived quality of the grant is statistically indistinguishable from grants that are funded.
R41	Small Business Technology Transfer (STTR) Grants - Phase I establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s).
R42	Small Business Technology Transfer (STTR) Grants - Phase II establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s).
R43	Small Business Innovation Research (SBIR) Grants - Phase I projects limited in time and amount, to establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s).
R44	Small Business Innovation Research (SBIR) Grants - Phase II in-depth development of R&D ideas whose feasibility has been established in Phase I and which are likely to result in commercial products or services.
U43	Small Business Innovation Research (SBIR) Cooperative Agreement - Phase I utilized when an assistance relationship will exist between the institute and a recipient and in which substantial programmatic involvement is anticipated between the institute and the recipient during performance of the contemplated activity.
U44	Small Business Innovation Research (SBIR) Cooperative Agreement - Phase II in-depth development of R&D ideas whose feasibility has been established in Phase I and which are likely to result in commercial products or services.

Cancer Centers by State (P30 Core Grants), Fiscal Year 2003

(Dollars in Thousands)

State	Grantee Institution	Type	Amount
Alabama	University of Alabama at Birmingham	Comprehensive	\$5,124
Arizona	University of Arizona	Comprehensive	3,750
California	Beckman Research Institute	Comprehensive	2,371
	Burnham Institute	Lab/Basic	3,044
	Salk Institute for Biological Sciences	Lab/Basic	2,689
	University of California Davis	Clinical	1,296
	University of California Irvine	Comprehensive	2,617
	University of California Los Angeles	Comprehensive	4,487
	University of California San Diego	Comprehensive	3,978
	University of California San Francisco	Comprehensive	7,771
	University of Southern California	Comprehensive	5,916
Colorado	University of Colorado System	Comprehensive	3,659
Connecticut	Yale University	Comprehensive	1,039
District of Columbia	Georgetown University	Comprehensive	2,908
Florida	University of South Florida	Comprehensive	2,285
Hawaii	University of Hawaii at Manoa	Clinical	1,964
Illinois	Northwestern University	Comprehensive	4,690
	University of Chicago	Clinical	4,116
Indiana	Indiana University - Purdue University at Indianapolis	Clinical	1,362
	Purdue University West Lafayette	Lab/Basic	1,139
Iowa	University of Iowa	Comprehensive	1,559
Maine	Jackson Laboratory	Lab/Basic	2,572
Maryland	Johns Hopkins University	Comprehensive	5,924
Massachusetts	Dana-Farber Cancer Institute	Comprehensive	10,287
	Massachusetts Institute of Technology	Lab/Basic	2,482
Michigan	University of Michigan at Ann Arbor	Comprehensive	5,055
	Wayne State University	Comprehensive	730
Minnesota	Mayo Clinic Rochester	Comprehensive	3,112
	University of Minnesota Twin Cities	Comprehensive	3,253
Missouri	Washington University	Clinical	1,385
Nebraska	University of Nebraska Medical Center	Clinical	1,532
New Hampshire	Dartmouth College	Comprehensive	1,871
New Jersey	Robert Wood Johnson Medical School	Comprehensive	2,679
New York	American Health Foundation	Lab/Basic	2,633
	Cold Spring Harbor Laboratory	Lab/Basic	3,742
	Columbia University Health Sciences	Comprehensive	1,768
	Kaplan Cancer Center/NYU	Clinical	2,502
	Roswell Park Cancer Institute Corp	Comprehensive	3,583
	Sloan-Kettering Institute for Cancer Research	Comprehensive	9,233
	Yeshiva University	Clinical	3,756
North Carolina	Duke University	Comprehensive	5,840
	University of North Carolina Chapel Hill	Comprehensive	5,296
	Wake Forest University	Comprehensive	1,483
Ohio	Case Western Reserve University	Comprehensive	3,949
	Ohio State University	Comprehensive	2,761
Oregon	Oregon Health & Science University	Clinical	1,228
Pennsylvania	Fox Chase Cancer Center	Comprehensive	7,730
	Thomas Jefferson University	Clinical	4,909
	University of Pennsylvania	Comprehensive	5,394
	University of Pittsburgh at Pittsburgh	Comprehensive	4,063
	Wistar Institute	Lab/Basic	2,466
Tennessee	St. Jude Children's Research Hospital	Clinical	4,849
	Vanderbilt University	Comprehensive	3,264
Texas	San Antonio Cancer Institute	Clinical	1,754
	University of Texas M.D. Anderson Cancer Center	Comprehensive	9,026
Utah	Huntsman Cancer Institute/University of Utah	Clinical	1,497
Vermont	University of Vermont & St. Agric College	Comprehensive	1,304
Virginia	University of Virginia Charlottesville	Clinical	2,056
	Virginia Commonwealth University/Massey Cancer Center	Clinical	2,262
Washington	Fred Hutchinson Cancer Research Center	Comprehensive	9,653
Wisconsin	University of Wisconsin Madison	Comprehensive	5,378
	Total P30s	61	222,024
	Total Planning Grants (P20s)		10,588
	Total Clinical Core Grants (P40/P41/U42)		3,064
	NCI Co-funded Awards with other NIH Institutes		130

Total Cancer Centers

\$235,806

Specialized Programs of Research Excellence, Fiscal Year 2003

(Dollars in Thousands)

In 1992, the NCI established the Specialized Programs of Research Excellence (SPORE). This program promotes interdisciplinary research and speeds the bidirectional exchange between basic and clinical science to move basic research findings from the laboratory to applied settings involving patients and populations. The goal of the SPORE program is to bring to clinical care settings novel ideas that have the potential to reduce cancer incidence and mortality, and to improve survival, and the quality of life.


Laboratory and clinical scientists work collaboratively to plan, design and implement research programs that impact on cancer prevention, detection, diagnosis, treatment and control. To facilitate this research, each SPORE develops and maintains specialized resources that benefit all scientists working on the specific cancer site, as well as SPORE scientists. An additional SPORE element is a career development program that recruits scientists both within and outside the SPORE institution to enlarge the cadre of laboratory and clinical scientists dedicated to translational research on human cancer. SPOREs meet annually to share data, assess research progress, identify new research opportunities and establish research priorities.

Mechanism	Site	No.	Amount
P50 SPOREs	Bladder	1	\$3,132
	Brain	2	4,228
	Breast	9	25,167
	Cervical	1	2,500
	Gastrointestinal	2	7,667
	Head and Neck	3	5,693
	Leukemia	1	2,500
	Lung	6	14,349
	Lymphoma	2	4,646
	Myeloma	1	2,250
	Ovarian	4	9,945
	Prostate	12	28,108
	Renal	1	2,500
	Skin	1	2,885
	Uterine	1	1,974
	Total P50s	47	117,544
P20 SPOREs	Brain		750
	Lung		1,000
	Pancreatic		3,300
		Total P20s	
	Subtotal	47	122,594
Co-funded	Urology with NIDDK		513
Total		47	\$123,107

NRSA Predoctoral and Postdoctoral Trainees


Fiscal Years 1994 - 2003

(Full Time Trainee Positions)



Construction/Renovation Funding Fiscal Years 1994 - 2003

(Dollars in Thousands)



	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
■ Grants	\$15,447	\$6,570	\$1,500	\$1,410	\$1,461	\$958	\$1,488	\$1,500	\$1,500	\$3,000
■ Contracts	1,002	1,430	1,500	1,590	1,500	2,042	2,012	1,500	3,500	2,000
Total	16,449	8,000	3,000	3,000	2,961	3,000	3,500	3,000	5,000	5,000

Grant and Contract Awards by State Fiscal Year 2003

(Dollars in Thousands)

State	Grants		Contracts		Total NCI		State
	No	Amount	No	Amount	No	Amount	
Alabama	87	\$44,317	16	\$11,270	103	\$55,587	Alabama
Alaska	2	1,651	0	0	2	1,651	Alaska
Arizona	78	39,597	4	1,815	82	41,412	Arizona
Arkansas	20	8,650	0	0	20	8,650	Arkansas
California	900	457,612	33	194,094	933	651,706	California
Colorado	113	34,796	2	5,126	115	39,922	Colorado
Connecticut	76	26,424	4	3,652	80	30,076	Connecticut
Delaware	7	2,007	0	0	7	2,007	Delaware
District of Columbia	81	30,043	17	11,083	98	41,127	District of Columbia
Florida	115	36,320	3	2,143	118	38,463	Florida
Georgia	62	22,238	9	3,850	71	26,088	Georgia
Hawaii	18	13,151	3	5,863	21	19,014	Hawaii
Idaho	1	131	0	0	1	131	Idaho
Illinois	227	93,878	16	7,166	243	101,044	Illinois
Indiana	57	17,921	0	0	57	17,921	Indiana
Iowa	47	17,086	5	4,778	52	21,864	Iowa
Kansas	24	7,546	4	2,739	28	10,284	Kansas
Kentucky	36	11,070	4	2,136	40	13,206	Kentucky
Louisiana	35	8,311	1	1,537	36	9,848	Louisiana
Maine	11	4,778	0	0	11	4,778	Maine
Maryland	237	113,125	73	104,654	310	217,779	Maryland
Massachusetts	629	303,337	9	2,518	638	305,855	Massachusetts
Michigan	206	85,250	11	18,366	217	103,616	Michigan
Minnesota	158	75,319	6	10,714	164	86,033	Minnesota
Mississippi	5	1,517	0	0	5	1,517	Mississippi
Missouri	121	44,420	10	12,980	131	57,400	Missouri
Montana	2	808	0	0	2	808	Montana
Nebraska	31	11,381	0	0	31	11,381	Nebraska
Nevada	6	1,858	0	0	6	1,858	Nevada
New Hampshire	49	25,616	1	178	50	25,795	New Hampshire
New Jersey	100	34,148	3	4,193	103	38,341	New Jersey
New Mexico	26	11,090	1	2,044	27	13,134	New Mexico
New York	653	282,935	15	7,792	668	290,728	New York
North Carolina	263	116,768	10	4,425	273	121,193	North Carolina
North Dakota	4	1,022	0	0	4	1,022	North Dakota
Ohio	275	96,722	9	5,707	284	102,429	Ohio
Oklahoma	16	3,927	1	102	17	4,029	Oklahoma
Oregon	62	19,948	0	0	62	19,948	Oregon
Pennsylvania	498	287,505	9	8,838	507	296,343	Pennsylvania
Rhode Island	51	16,862	0	0	51	16,862	Rhode Island
South Carolina	39	11,269	0	0	39	11,269	South Carolina
South Dakota	5	3,611	0	0	5	3,611	South Dakota
Tennessee	171	78,874	3	1,118	174	79,992	Tennessee
Texas	433	220,792	10	5,558	443	226,350	Texas
Utah	45	21,450	2	3,777	47	25,227	Utah
Vermont	15	8,785	0	0	15	8,785	Vermont
Virginia	106	32,710	9	26,922	115	59,631	Virginia
Washington	238	130,146	6	6,808	244	136,954	Washington
West Virginia	3	1,057	1	1,400	4	2,457	West Virginia
Wisconsin	118	48,459	5	4,830	123	53,289	Wisconsin
Wyoming	2	152	0	0	2	152	Wyoming
Total	6,564	2,968,389	315	490,178	6,879	3,458,567	Total
Guam	1	299	0	0	1	299	Guam
Puerto Rico	3	2,592	0	0	3	2,592	Puerto Rico
Total	6,568	2,971,280	315	490,178	6,883	3,461,458	Total

Excludes NRSA TAP, Loan Repayment Program, Foreign Contracts and Grants, and Program Evaluation.

Grant and Contract Awards by Country Fiscal Year 2003

(Dollars in Thousands)

Country	Grant		Contract		Total NCI		Country
	No	Amount	No	Amount	No	Amount	
Argentina		\$67				\$67	Argentina
Australia	15	3,965			15	3,965	Australia
Belgium	1	439			1	439	Belgium
Canada	15	6,760	2	\$659	17	7,419	Canada
China			1	25	1	25	China
Costa Rica			1	3,424	1	3,424	Costa Rica
Denmark			1	146	1	146	Denmark
Finland			2	512	2	512	Finland
France	7	2,441			7	2,441	France
Israel	5	766			5	766	Israel
Japan			1	162	1	162	Japan
Mexico		18				18	Mexico
Netherlands	2	158			2	158	Netherlands
New Zealand			1	120	1	120	New Zealand
Senegal	1	54			1	54	Senegal
South Africa	1	198			1	198	South Africa
Spain	1	180			1	180	Spain
Sweden	3	527	2	522	5	1,049	Sweden
Switzerland	1	42			1	42	Switzerland
Taiwan				100		100	Taiwan
United Kingdom	3	660			3	660	United Kingdom
West Indies			1	700	1	700	West Indies
Total Foreign	55	\$16,273	12	\$6,370	67	\$22,645	

Institutions Receiving More than \$15 Million in NCI Support, FY 2003

(Dollars in Thousands)

State	Institution	Grants	Contracts	Total NCI
Alabama	University of Alabama at Birmingham	\$36,338	\$8,064	\$44,402
Arizona	University of Arizona	33,035	1,329	34,364
California	Beckman Research Inst of City of Hope	15,672		15,672
	Burnham Institute	17,955	733	18,688
	National Childhood Cancer Foundation	40,288		40,288
	Science Applications International Corporation		164,744	164,744
	Scripps Research Institute	23,231	945	24,176
	Stanford University	36,297		36,297
	University of California System	161,759	2,868	164,627
	University of Southern California	41,921	4,046	45,967
Colorado	University of Colorado Health Sciences Center	21,408	4,072	25,480
Connecticut	Yale University	22,886	1,254	24,141
Dist of Columbia	Georgetown University	20,099	2,649	22,748
Georgia	Emory University	13,135	2,131	15,265
Illinois	Northwestern University	24,152	1,215	25,367
	University of Chicago	38,323	1,310	39,634
	University of Illinois at Chicago	16,204	2,473	18,677
Iowa	University of Iowa	15,016		15,016
Maryland	Johns Hopkins University	80,173	2,677	82,850
Massachusetts	Beth Israel Deaconess Medical Center	19,788		19,788
	Brigham & Women's Hospital	35,219		35,219
	Dana-Faber Cancer Institute	68,366		68,366
	Harvard University	34,825		34,825
	Massachusetts General Hospital	37,979	838	38,817
	Massachusetts Institute of Technology	16,869		16,869
Michigan	University of Michigan at Ann Arbor	57,052	5,637	62,689
	Wayne State University	14,697	6,220	20,917
Minnesota	Mayo Clinic Rochester	48,197	2,383	50,580
	University of Minnesota Twin Cities	23,042	8,331	31,373
Missouri	Washington University	31,581	9,134	40,715
New Hampshire	Dartmouth College	24,689	178	24,868
New York	Columbia University Health Sciences	25,606		25,606
	Mount Sinai School of Medicine	21,124		21,124
	New York University School of Medicine	17,691		17,691
	Roswell Park Cancer Institute Corp	29,246		29,246
	Sloan-Kettering Institute for Cancer Research	59,733	2,629	62,362
	Yeshiva University	28,607		28,607
North Carolina	Duke University	59,643	1,073	60,716
	University of North Carolina Chapel Hill	37,172	272	37,444
Ohio	Case Western Reserve University	28,645		28,645
	Ohio State University	31,425	858	32,283
Pennsylvania	American College of Radiology	40,026		40,026
	Fox Chase Cancer Center	27,480	2,803	30,283
	NSABP Foundation, Inc.	19,171		19,171
	Thomas Jefferson University	24,195	731	24,926
	University of Pennsylvania	71,549	1,546	73,095
	University of Pittsburgh at Pittsburgh	38,536	3,758	42,294
Tennessee	St. Jude Children's Research Hospital	25,050		25,050
	Vanderbilt University	46,064		46,064
Texas	Baylor College of Medicine	32,613	216	32,829
	CTRC Research Foundation	36,047		36,047
	University of Texas MD Anderson Cancer Center	98,369	4,108	102,476
Utah	University of Utah	20,749	3,777	24,526
Virginia	University of Virginia Charlottesville	19,253		19,253
Washington	Fred Hutchinson Cancer Research Center	80,970	5,548	86,519
	University of Washington	29,781	783	30,563
Wisconsin	University of Wisconsin Madison	37,923	2,735	40,658
	Total	\$2,056,867	\$264,066	\$2,320,934

Includes Manpower Development Grants

Appropriations of the NCI 1938-2003

(In Whole Dollars)

1938 - 1969	\$1,875,699,720	
1970 - 1979	6,073,870,500	
1980 - 1989	11,958,860,000	
1990.....	1,664,000,000	<i>prior to reductions in PL 101-166 (-\$6,839,000) and PL101-239 (-\$22,829,000).</i>
1991.....	1,766,324,000	<i>prior to reductions in PL 101-517 (-\$8,972,000 for salary and expense reduction; -\$42,568,000 for across-the-board reduction).</i>
1992.....	1,989,278,000	<i>prior to reductions in PL 102-170 (-\$21,475,000 for salary and expense reduction; -\$1,262,000 for travel reduction; \$15,000,000 transferred to other institutes for cancer research).</i>
1993.....	2,007,483,000	<i>prior to reductions in PL 102-294 (-\$16,060,000 for .8% reduction to all line items, -\$9,933,000 for S&E reduction, -\$139,000 for consultant services reduction).</i>
1994.....	2,082,267,000	<i>prior to reduction in PL103-211 (-\$5,885,000 administration reduction).</i>
1995.....	2,135,119,000	<i>prior to reductions in PL 103-211 (-\$1,883,000 for Procurement reduction; -\$116,000 for SLUC reduction; -\$1,052,000 for Bonus Pay reduction). Includes \$218,199,000 of AIDS funding.</i>
1996.....	2,251,084,000	<i>Includes \$225,790,000 of AIDS funding.</i>
1997.....	2,382,532,000	<i>Includes \$224,983,000 of AIDS funding.</i>
1998.....	2,547,314,000	<i>prior to reductions in PL 105-119 (-\$4,755,000 via the Secretary's 1% transfer authority). Includes \$8,699,000 transferred via the NIH Director's 1% transfer authority, \$41,000 transfer from U.S. Dept. of State in PL 105-119, and \$226,414,000 of AIDS funding.</i>
1999.....	2,927,187,000	<i>prior to reductions in PL 106-51 (-\$1,940,000 for travel and admin. expenses). Includes -\$931,000 transferred via the Secretary 1% transfer authority, and -\$6,259,000 transferred via the NIH Director's 1% transfer authority, and \$239,190,000 of AIDS funding.</i>
1990 - 1999	21,752,588,000	
2000.....	3,332,317,000	<i>prior to reductions in PL 106-113 (-\$17,763,000 for across the board reduction). Includes \$245,804,000 of AIDS funding.</i>
2001.....	3,757,242,000	<i>prior to reductions in PL 106-554(-\$2,005,000 for across-the-board reduction). Includes -\$711,000 Secretary's 1% transfer, -\$781,000 transfer for Office of Human Research Protection and -\$24,000 lapse. Includes \$255,960,000 of AIDS funding.</i>
2002.....	4,190,405,000	<i>prior to reductions in PL 107-116(-\$4,524,000 via the Secretary's 1% transfer authority, -\$2,054,000 for the enacted rescission, -\$7,118,000 administrative reduction and -\$8,000 lapse). Includes \$254,396,000 of AIDS funding.</i>
2003.....	4,622,394,000	<i>prior to reductions in PL 108-7(-\$30,046,000 for the enacted rescission and -\$2,000 lapse). Includes \$263,442,000 of AIDS funding.</i>
1938-2003	57,563,376,220	


By-Pass Budget Requests Fiscal Years 1973-2005

(In Whole Dollars)

Fiscal Year	Request
1973.....	\$550,790,000
1974.....	640,031,000
1975.....	750,000,000
1976.....	898,500,000
1977.....	948,000,000
1978.....	955,000,000
1979.....	1,036,000,000
1980.....	1,055,000,000
1981.....	1,170,000,000
1982.....	1,192,000,000
1983.....	1,197,000,000
1984.....	1,074,000,000
1985.....	1,189,000,000
1986.....	1,460,000,000
1987.....	1,570,000,000
1988.....	1,700,000,000
1989.....	2,080,000,000
1990.....	2,195,000,000
1991.....	2,410,000,000
1992.....	2,612,000,000
1993.....	2,775,000,000
1994.....	3,200,000,000
1995.....	3,600,000,000
1996.....	3,640,000,000
1997.....	2,977,000,000
1998.....	2,702,500,000
1999.....	3,191,000,000
2000.....	3,873,000,000
2001.....	4,135,000,000
2002.....	5,030,000,000
2003.....	5,690,000,000
2004.....	5,986,000,000
2005.....	6,211,000,000

The National Cancer Act in December 1971, included a provision for the Director, NCI to submit an annual budget request directly to the President, with comment only by NIH and DHHS. This Bypass Budget was first submitted for 1973.

Bypass Requests and Appropriations of the NCI Fiscal Years 1973-2005





Comparison of Dollars, Positions and Space Fiscal Years 1993-2003

Funds are obligations against the annual appropriation in millions of dollars

FTEs are the number of workyears for appointed employees of the NCI. A workyear equals 2,080 hours.

The increase in FTEs in FY 2000 is due to the fact that 195 contract staff were converted to NCI appointments.

Space is in thousands of square feet, excluding NCI-Frederick.



Personnel Resources
Fiscal Years 1995-2003

Fiscal Year	Full Time Appointment	Part Time Appointment	Training Fellows	Total Personnel Resources
1995	1,767	483	1,055	3,305
1996	1,841	460	960	3,261
1997	1,915	422	1,023	3,360
1998	1,921	466	1,124	3,511
1999	1,941	628	1,060	3,629
2000	2,139	831	1,202	4,172
2001	2,224	912	963	4,099
2002	2,250	979	949	4,178
2003	2,193	1,073	1,191	4,457

AIDS Funding History

Fiscal Years 1993-2003

(Dollars in Thousands)

Fiscal Year	NCI	NIH	% NCI of NIH
1993	\$173,029	\$1,073,957	16%
1994	212,868	1,298,996	16%
1995	217,430	1,333,600	16%
1996	225,360	1,411,860	16%
1997	224,733	1,501,073	15%
1998	225,991	1,559,071	14%
1999	239,190	1,797,422	13%
2000	244,145	2,005,100	12%
2001	237,789	2,244,160	11%
2002	254,396	2,500,866	10%
2003	263,442	2,718,171	10%

